Preparation and utilization of ginseng peptides and ginseng peptide-like peptides

Through solid-phase peptide synthesis and recombination technology, the natural disulfide bond of ginseng peptide is formed under nonaqueous conditions, which solves the problem of preparation and isolation of ginseng peptides and realizes its biological activity and multifunctional application.

CN110461861BActive Publication Date: 2024-11-15NANYANG TECH UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201780082437.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2016-11-09
Filing Date
2017-11-09
Publication Date
2024-11-15
Estimated Expiration
2037-11-09

AI Technical Summary

Technical Problem

The prior art is difficult to efficiently prepare and isolate ginseng peptides, and their biological activities have not been fully developed.

Method used

Using solid-phase peptide synthesis method and recombinant technology, ginseng peptides are synthesized on solid support by stepping coupling amino acids, and organic oxidation folding is carried out under nonaqueous conditions to form natural disulfide bond linkages, while chromatography and purification methods are used to synthesize ginseng plants. Ginseng peptides are enriched.

Benefits of technology

It has achieved efficient synthesis and separation of ginseng peptides, maintained its natural disulfide bond structure and biological activity, and is used for a variety of medicinal and health care purposes, such as vasodilation, antithrombosis, anti-atherosclerosis and anti-aging.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0002119804630000111
    Figure BDA0002119804630000111
  • Figure BDA0002119804630000121
    Figure BDA0002119804630000121
  • Figure BDA0002119804630000131
    Figure BDA0002119804630000131
Patent Text Reader

Abstract

The present invention relates to a method for solid phase peptide synthesis or recombinant production of ginseng peptide or ginseng peptide analogous peptide or salt thereof. Also provided is the use of ginseng peptide or ginseng peptide analogous peptide or salt thereof as α1-adrenergic receptor antagonist and vasodilator, nitric oxide promoter, anti-thrombotic agent, anti-atherosclerotic agent, as protective agent against doxorubicin-induced cardiotoxicity, anti-aging and physiological regulator, nutritious food, health care product or cosmetic ingredient.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application cites and claims the benefit of priority from Singaporean patent application No. 10201609388X filed on November 9, 2016, the contents of which are incorporated herein by reference for all purposes including the incorporation under PCT Rule 4.18 of any element or part not contained in the description, claims or drawings herein and in accordance with PCT Rule 20.5(a). Technical Field

[0003] The present invention generally relates to a method for solid phase peptide synthesis or recombinant generation of ginseng peptides or ginseng peptide-like peptides or their salts having natural disulfide bonds, and uses of the prepared ginseng peptides or ginseng peptide-like peptides or their salts. Background Art

[0004] Ginseng is a traditional herbal remedy that has been used for thousands of years. It is one of the most widely used and valuable medicinal plants. Due to its exceptionally long and widespread use, ginseng has been shown to be generally safe.

[0005] Plant peptides and proteins have been underexplored as bioactive components of medicinal plants. Ginsentides are a class of cysteine-rich peptides found in ginseng that can serve as a precursor to bioactive peptide and drug discovery. However, isolating ginsentides from plants is typically laborious and expensive. Therefore, there is a need in the art for methods to prepare ginsentides. Summary of the Invention

[0006] The present invention satisfies the above-mentioned needs in the art by providing a synthesis and recombination method for preparing ginseng peptide or ginseng peptide-like peptide and its use.

[0007] In a first aspect, the present invention relates to a solid phase peptide synthesis method of ginseng peptide or ginseng peptide analogous peptide or a pharmaceutically acceptable salt thereof, the method comprising the following steps:

[0008] (a) synthesizing the ginseng peptide or ginseng peptide-like peptide on a solid support by stepwise coupling of Fmoc (fluorenylmethoxycarbonyl)-protected, optionally further appropriately side-chain-protected amino acids, dipeptides and / or oligopeptides in a linear C-terminal to N-terminal manner, wherein a glycine residue is added at position 24 of SEQ ID NO: 1 mediated by Fmoc-(Dmb)Gly-OH;

[0009] (b) cleaving the ginseng peptide or ginseng peptide-like peptide from the solid support and deprotecting the peptide; and subsequently,

[0010] (c) The ginseng peptide or the ginseng peptide-like peptide undergoes organic oxidative folding to form a native disulfide linkage.

[0011] In various embodiments, step (a) comprises the following steps:

[0012] (i) deprotecting the first amino acid attached to the solid support by removing a protective chemical group from the first amino acid;

[0013] (ii) activating a chemical group on a second amino acid to prepare the second amino acid coupled to the first amino acid;

[0014] (iii) coupling the activated second amino acid to the deprotected first amino acid to form a peptide consisting of the first and second amino acids; and

[0015] (iv) successively deprotecting and coupling multiple amino acids into the growing peptide chain until the ginseng peptide or ginseng peptide-like peptide is synthesized.

[0016] In various embodiments, the method comprises promoting at least one of the deprotecting, activating, and coupling steps by applying microwave energy.

[0017] In various embodiments, the organic oxidative folding is performed under non-aqueous conditions and in an organic solvent.

[0018] In various embodiments, the organic oxidative folding comprises folding the ginseng peptide or ginseng peptide-like peptide in an organic solvent containing cysteamine and / or morpholine, preferably dimethyl sulfoxide (DMSO) and / or isopropanol.

[0019] In various embodiments, the organic oxidative folding is performed at 4°C.

[0020] In various embodiments, the method comprises purifying the folded ginseng peptide or ginseng peptide-like peptide or salt thereof, preferably by reverse phase high performance liquid chromatography (RP-HPLC).

[0021] In a second aspect, the present invention relates to a method for recombinantly preparing ginseng peptide or ginseng peptide-like peptide or a pharmaceutically acceptable salt thereof, the method comprising the following steps:

[0022] (a) providing a host cell comprising a polynucleotide, wherein the polynucleotide encodes a polypeptide comprising a maltose binding protein having an amino acid sequence as shown in SEQ ID NO: 65, an enterokinase cleavage sequence having an amino acid sequence as shown in SEQ ID NO: 66, and the ginseng peptide or ginseng peptide-like peptide or a salt thereof;

[0023] (b) cultivating the host cell in a growth medium under conditions permitting expression of the polypeptide, and recovering the polypeptide from the medium; and

[0024] (c) cleaving the polypeptide using enterokinase to produce the ginseng peptide or ginseng peptide-like peptide or a salt thereof.

[0025] In various embodiments, the polypeptide has an amino acid sequence as shown in any one of SEQ ID NOs: 67-80.

[0026] In various embodiments, the method further comprises purifying the recombinantly produced polypeptide prior to the enterokinase cleavage, preferably by purification using an amylose resin.

[0027] In various embodiments, the method further comprises purifying the ginseng peptide or ginseng peptide-like peptide or salt thereof by anion exchange chromatography and / or reverse phase chromatography after the enterokinase cleavage.

[0028] In a third aspect, the present invention relates to the use of ginseng peptides or ginseng peptide-like peptides or pharmaceutically acceptable salts thereof or enriched fractions obtained from ginseng plants or plants containing ginseng peptides or ginseng peptide-like peptides by chromatography, size exclusion or purification-related methods as α1-adrenergic receptor antagonists and vasodilators.

[0029] In a fourth aspect, the present invention relates to the use of ginseng peptides or ginseng peptide-like peptides or pharmaceutically acceptable salts thereof or enriched fractions obtained from ginseng plants or plants containing ginseng peptides or ginseng peptide-like peptides by chromatography, size exclusion or purification-related methods as nitric oxide promoters.

[0030] In a fifth aspect, the present invention relates to the use of ginseng peptides or ginseng peptide-like peptides or pharmaceutically acceptable salts thereof or enriched fractions obtained from ginseng plants or plants containing ginseng peptides or ginseng peptide-like peptides by chromatography, size exclusion or purification-related methods as anti-thrombotic agents.

[0031] In a sixth aspect, the present invention relates to the use of ginseng peptides or ginseng peptide-like peptides or pharmaceutically acceptable salts thereof or enriched fractions obtained from ginseng plants or plants containing ginseng peptides or ginseng peptide-like peptides by chromatography, size exclusion or purification-related methods as anti-atherosclerotic agents.

[0032] In the seventh aspect, the present invention relates to the use of ginseng peptides or ginseng peptide-like peptides or pharmaceutically acceptable salts thereof or enriched fractions obtained from ginseng plants or plants containing ginseng peptides or ginseng peptide-like peptides by chromatography, size exclusion or purification-related methods as protective agents against doxorubicin (DOX)-induced cardiotoxicity.

[0033] In the eighth aspect, the present invention relates to the use of ginseng peptides or ginseng peptide-like peptides or pharmaceutically acceptable salts thereof or enriched fractions obtained from ginseng plants or plants containing ginseng peptides or ginseng peptide-like peptides by chromatography, size exclusion or purification-related methods as anti-aging and physiological regulators.

[0034] In the ninth aspect, the present invention relates to the use of ginseng peptides or ginseng peptide-like peptides or pharmaceutically acceptable salts thereof or enriched fractions obtained from ginseng plants or plants containing ginseng peptides or ginseng peptide-like peptides by chromatography, size exclusion or purification-related methods as nutritional food, health product or cosmetic ingredients.

[0035] According to all the above aspects of the present invention, the ginseng peptide or the ginseng peptide-like peptide has (i) an amino acid sequence shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73% or 74%, preferably at least 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83% or 84%, even more preferably at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93% or 94%, most preferably at least 95%, 96%, 97%, 98% or 99% sequence identity with the entire sequence of the peptide (i). BRIEF DESCRIPTION OF THE DRAWINGS

[0036] The present invention may be better understood by reference to the detailed description taken in conjunction with the non-limiting examples and accompanying drawings.

[0037] Figure 1 Schematic diagram of the physiological regulation effect of ginseng peptide. TP1: SEQ ID NO: 1.

[0038] Figure 2 .Schematic flow chart of chemical synthesis of ginseng peptides.

[0039] Figure 3 .Oxidative folding strategy for the synthesis of ginseng peptide TP1.

[0040] Figure 4 Comparison of natural and synthetic ginseng peptide TP1 using UHPLC and MALDI-MS.

[0041] Figure 5 Comparison of natural and synthetic ginseng peptide TP1 using 1D and 2D NMR.

[0042] Figure 6 Comparative study on the function of natural and synthetic ginseng peptide TP1 in nitric oxide production.

[0043] Figure 7Recombinant expression scheme of ginseng peptide. Peptide DDDDK: SEQ ID NO: 66.

[0044] Figure 8 .IPTG induced the expression of maltose binding protein-TP1 fusion protein.

[0045] Figure 9 Purification of maltose binding protein-TP1 fusion protein using an amylose column. S - cell lysate; FT - column flow-through; W1 - first wash; W2 - second wash; E - eluted protein.

[0046] Figure 10 .Enterokinase removes the maltose binding protein tag.

[0047] Figure 11 .Mass spectra before and after enterokinase cleavage.

[0048] Figure 12 RP-HPLC and MALDI-TOF MS spectra of native and reduced kB1. Panels A and B show the RP-HPLC spectra of native and reduced kB1, with "N" and "R" representing native and reduced, respectively. Panels C and D show the MS spectra of native and reduced kB1, with "N" and "R" representing native and reduced, respectively. Panels C and D show the MS spectra of peaks N and R, respectively. Panels E and F are zoomed-in views of the MS results in panels C and D, demonstrating the difference between the two masses.

[0049] Figure 13 RP-UPLC chromatograms of the oxidative refolding of kB1, demonstrating the effects of different bases. A. Conditions containing varying concentrations of pyridine (5-50%); B. Conditions containing varying concentrations of imidazole (5-15%); C. Conditions containing varying concentrations of morpholine (5-30%). All conditions contained 100 μM peptide, 100 mM cysteamine, and 10% (v / v) DMSO. The chromatograms show reactions run for 1 hour. "R" and "N" denote the reduced and native forms of kB1. "I" denotes an intermediate form of kB1.

[0050] Figure 14 RP-UPLC profile of the oxidative folding of kB1, showing the effects of cysteamine and DMSO as redox agents. "R" and "N" denote the reduced and native forms of kB1, while "I" denotes a folding intermediate.

[0051] Figure 15RP-HPLC profiles of the oxidative folding of kB1 using different thiols as reducing agents. A. Reduced kB1; B. Conditions containing 10 mM thiolacetic acid; C. Conditions containing 10 mM 2-thiolethanol; D. Conditions containing 10 mM cysteamine. "R" and "N" denote the reduced and native forms of kB1, while I denotes a folding intermediate. All conditions contained 100 μM peptide, 100 mM thiol, 10% (v / v) DMSO, 85% 2-propanol, and 5% morpholine.

[0052] Figure 16 .Natural kB1 (red) and synthetic (blue) 1 Comparison of H NMR spectra. The two peptides were dissolved in 90% H2O / 10% deuterated water at pH 4.3. Spectra were acquired at 298 K using an NMR spectrometer (600 MHz).

[0053] Figure 17 .Scheme for purification of ginseng peptides from plant materials.

[0054] Figure 18 . Ginseng peptides TP1, TP3 and TP8 have antagonistic effects on phenylephrine-induced aortic ring contraction.

[0055] Figure 19 . Ginseng peptide TP1 has no antagonistic effect on KCl-induced aortic ring contraction.

[0056] Figure 20 .Deuterium exchange of ginseng peptide TP1 by 1D NMR.

[0057] Figure 21 Amino acid sequences of the primary and secondary structures of ginseng peptides, their secondary and tertiary structures (top left), the overall layout of synthetic and natural TP1 (top right), a CPK model of the hydrophobic surface of TP1 (center), and the 3D structures of TP5 and TP8 determined by NMR (bottom). TP1: SEQ ID NO: 1.

[0058] Figure 22 Mass spectra of aqueous extracts of the roots of (A) Panax ginseng, (B) American ginseng, and (C) Panax notoginseng using MALDI-TOF MS.

[0059] Figure 23 Mass spectra of aqueous extracts of ginseng (A) roots, (B) seeds, (C) leaves, and (D) flowers using MALDI-TOF MS.

[0060] Figure 24De novo sequencing of the human ginseng peptide TP1. Enzymatic digestion of the S-reduced peptide with chymotrypsin and trypsin each produced a major fragment with m / z values ​​of 2459 (SEQ ID NO: 131) and 2831 (SEQ ID NO: 132), respectively. The fragment sequences were deduced using the b- and y-ions generated by MALDI-TOF MS / MS.

[0061] Figure 25 (A) HPLC profiles of partially S-reduced and S-alkylated human ginseng peptide TP1. Peaks 1, 2, 3, N, and RA contain the 3SS, 2SS, 1SS, native peptide, and fully S-NEM-alkylated peptide, respectively. A schematic diagram showing the disulfide mapping of human ginseng peptide TP1 is also shown; (B) The putative unfolding pathway of human ginseng peptide TP1 determined by disulfide linkage mapping. Under our experimental conditions, the Cys I-IV bond is first reduced to generate a 3SS species, followed by the Cys V-VIII bond to generate a 2SS species, then the Cys III-VII bond to generate a 1SS species, and finally the Cys II-VI bond. TP1: SEQ ID NO: 1.

[0062] Figure 26 Transcripts encoding ginseng peptides from Panax ginseng, American ginseng, and Panax notoginseng were inferred from de novo assembly of transcriptome data from the NCBI database. Transcriptome data used were as follows: Panax notoginseng flower (SRX378878), American ginseng flower (SRX062267), Panax ginseng flower (SRX181263), Panax ginseng flower (SRX378873), Panax notoginseng leaf (SRX378880), American ginseng seed (SRX529365), and Panax ginseng root (ERX137460). SPase: signal peptidase. Amino acid sequences are shown in SEQ ID NOs: 133-146.

[0063] Figure 27 Ginseng peptide TP1 was shown to increase cellular NO production in human endothelial cells (HUVEC-CS). In comparison, ginseng peptide TP1 exhibited three times the potency and NO release of ginsenosides Rb1 and Rg1. Ginseng peptides TP1, TP3, TP8, and synthetic TP1 demonstrated similar cellular NO release.

[0064] Figure 28 Ginseng peptide TP1 activates endothelial nitric oxide synthase. Representative Western blot analysis of the dose- and time-dependent effects of ginseng peptide TP1 on phosphorylated endothelial nitric oxide synthase (p-eNOS) accumulation in HUVEC-CS cells. All results are presented as the mean ± SEM of three independent experiments. *P < 0.05 compared with the ginseng peptide TP1-treated group.

[0065] Figure 29Ginseng peptide TP1-induced nitric oxide production involves PI3K / Akt signaling. HUVEC-CS cells were exposed to ginseng peptide TP1 and (A) MK 2206 (Akt inhibitor) or (B) LY294002 (PI3K inhibitor) for 1 hour. Intracellular NO production was measured by DAF-2DA staining and expressed as normalized fluorescence intensity. (C) Representative Western blot analysis of the time-dependent effect of ginseng peptide TP1 on Akt phosphorylation in HUVEC-CS cells. All results are expressed as the mean ± SEM of three independent experiments. *P < 0.05 compared to the ginseng peptide TP1-treated group.

[0066] Figure 30 .Deuterium exchange of ginseng peptide TP1 by 1D NMR.

[0067] Figure 31 Ginseng peptide TP1 showed no cytotoxicity or hemolytic effects on (A) Huh7 cells. Ginseng peptide TP1 did not induce the release of (C) IL-6, (D) IL-8, (E) IL-10, and (F) TNF-α from THP-1 cells. LPS was used as a positive control. All results are expressed as mean ± SEM (N = 3). *P < 0.05 compared with the control group.

[0068] Figure 32 Ginseng peptide TP1 antagonizes P2y12 activation. A P2y12 inhibitory protein biosensor assay, using 6.4 nM 2-methylthio-ADP-induced P2y12 activation, was used to detect ginseng peptide TP1 and ginsenosides Rb1 and Rg1 in antagonist mode. P2y12 activation was measured by relative luminescence units and expressed as inhibition relative to blank.

[0069] Figure 33 .D2O exchange of ginseng peptide TP1 by 1D NMR.

[0070] Figure 34 Ginseng peptide TP1 inhibits platelet aggregation in vivo. 10 mg / kg of ginseng peptide TP1 was intravenously injected into SD rats for 20 minutes. Platelet-rich plasma was separated by centrifugation. Platelet aggregation was examined under stimulation with ADP or arachidonic acid.

[0071] Figure 35 Pull-down assays analyzed by LC-MS / MS and Western blot revealed that the ginseng peptide TP1 interacts with endothelial cell selective adhesion molecules.

[0072] Figure 36Ginseng peptide TP1 inhibits the adhesion of basal monocytes to endothelial cells. Ginseng peptide TP1 was co-incubated with CFSE-labeled THP-1 monocytes and HUVEC-CS endothelial cell monolayers for 1 hour. Adhesion inhibitory peptide (GRGDSP) was used as a control.

[0073] Figure 37 Heparin binding properties of ginseng peptides using a heparin HPLC affinity column. Ginseng peptides TP1, TP3, and TP9 were retained on the heparin HPLC affinity column, while TP2, TP5, TP8, and SIGGIR (negative control) were not retained.

[0074] Figure 38 (A) Modeling of the interaction between human ginseng peptide TP1 (SEQ ID NO: 1) and heparin sulfate using the ClusPro version 2.0 server. (B) Heparin binding comparison of the synthetic peptide Ac-KSGGAW-NH2 (SEQ ID NO: 147) and its alanine-substituted analogs (Ac-ASGGAW-NH2 (SEQ ID NO: 148), Ac-KAGGAW-NH2 (SEQ ID NO: 149), and Ac-KSGGAA-NH2 (SEQ ID NO: 150)) using a heparin HPLC affinity column.

[0075] Figure 39 Representative images of zebrafish embryos after doxorubicin treatment with or without ginseng peptide.

[0076] Figure 40 .Heartbeat of zebrafish embryos after treatment with ginseng peptide.

[0077] Figure 41 Comparison of ventricular contractility after co-treatment with doxorubicin and ginseng peptide.

[0078] Figure 42 .Cell viability of H9c2 cells after treatment with ginseng peptides or ginsenosides.

[0079] Figure 43 .Cell viability of H9c2 cells after co-treatment with doxorubicin and ginsenosides Rg1, Rb1 and Re.

[0080] Figure 44 Effects of ginseng peptides on cell viability in doxorubicin-treated breast cancer cell line (MDA-MB-231).

[0081] Figure 45 .Plasma concentrations of ginseng peptides in mice after intravenous and oral administration.

[0082] Figure 46Effect of ginseng peptide (TP1) on the HUVEC-CS cell proteome. Cells were treated with ginseng peptide, and the whole-cell proteome was analyzed using a TMT-based quantitative proteomics approach. (a) TMT ratio distribution of the dataset presented in this paper. (b) Differentially expressed proteins in HUVEC-CS cells during ginseng peptide treatment. (c) Functional classification of differentially regulated proteins after ginseng peptide treatment. (d) Relative protein levels of telomere repeat binding factor 2 after ginseng peptide treatment.

[0083] Figure 47 .Effect of ginseng peptide (TP1) on the proteome of hypoxic HUVEC-CS cells.

[0084] Figure 48 .Effect of ginseng peptide on adhesion of leukocytes to hypoxic endothelial cells.

[0085] Figure 49 Effects of ginseng peptides on hypoxia-induced adhesion molecule expression in endothelial cells.

[0086] Figure 50 .Effects of ginseng peptides on the accumulation of unfolded proteins in hypoxic endothelial cells.

[0087] Figure 51 .Effects of ginseng peptides on the unfolded protein response pathway in hypoxic endothelial cells.

[0088] Figure 52 .Effects of ginseng peptides on endothelial cell apoptosis pathway.

[0089] Figure 53 .Effect of ginseng peptide on the survival rate of hypoxic endothelial cells.

[0090] Figure 54 .Ginseng peptides reduce unfolded proteins in cardiomyocytes, vascular smooth muscle cells, and myocytes.

[0091] Figure 55 .Ginseng peptides reduce the production of reactive oxygen species in hypoxic endothelial cells.

[0092] Figure 56 .Ginseng peptides increase nitric oxide production in hypoxic endothelial cells.

[0093] Figure 57 Ginseng peptide-like precursor sequences from NCBI and OneKp transcriptome databases. Amino acid sequences are shown in SEQ ID NOs: 151-200. DETAILED DESCRIPTION

[0094] The following detailed description relates to specific details and embodiments that the present invention may implement by way of example. These embodiments are described in sufficient detail to enable those skilled in the art to implement the present invention. Other embodiments may be used and structural and logical changes may be made without departing from the scope of the present invention. Various embodiments are not necessarily mutually exclusive, as some embodiments may be combined with one or more other embodiments to form new embodiments.

[0095] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. The singular terms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Similarly, the word "or" also includes "and" unless the context clearly dictates otherwise. The term "comprising" means "including." In the event of a conflict, the present specification, including the interpretation of the term, shall control.

[0096] In a first aspect, the present invention relates to a solid phase peptide synthesis method of a ginseng peptide or a ginseng peptide analogous peptide or a pharmaceutically acceptable salt thereof, wherein the ginseng peptide or ginseng peptide analogous peptide has (i) an amino acid sequence shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, preferably at least 75%, even more preferably at least 85%, and most preferably at least 95% sequence identity with the entire sequence of the peptide (i), wherein the method comprises the following steps:

[0097] (a) synthesizing a ginseng peptide or a ginseng peptide-like peptide on a solid support by stepwise coupling of Fmoc-protected, optionally further appropriately side-chain-protected amino acids, dipeptides and / or oligopeptides in a linear C-terminal to N-terminal manner, wherein a glycine residue is added at position 24 of SEQ ID NO: 1 mediated by Fmoc-(Dmb)Gly-OH (Dmb: dimethoxybenzyl);

[0098] (b) cleaving the ginseng peptide or ginseng peptide-like peptide from the solid support and deprotecting the peptide; and subsequently,

[0099] (c) Ginseng peptide or ginseng peptide-like peptide undergoes organic oxidative folding to form native disulfide linkages.

[0100] The terms "peptide," "polypeptide," and "protein" are used interchangeably herein to refer to a polymer of at least two amino acids linked by a peptide bond. The term also includes naturally or artificially modified amino acid polymers; for example, by disulfide bond formation, glycosylation, lipidation, acetylation, or phosphorylation. The term "amino acid" refers to natural and / or non-natural or synthetic amino acids, including D and L optical isomers, amino acid analogs (e.g., norleucine is an analog of leucine), and derivatives known in the art. As used herein, the term "naturally occurring amino acid" refers to the 20 naturally occurring L-amino acids, namely Gly (G), Ala (A), Val (V), Leu (L), Ile (I), Phe (F), Cys (C), Met (M), Pro (G), Thr (T), Ser (S), Glu (E), Gln (Q), Asp (D), Asn (N), His (H), Lys (K), Arg (R), Tyr (Y), and Trp (W). Generally, in the context of this application, peptides and polypeptides are shown in an N- to C-terminal direction.

[0101] As used herein, the term "pharmaceutically acceptable salt" refers to salts of the target peptide that are safe and effective for administration to mammals and possess the desired biological activity.

[0102] The term "sequence identity" as used herein refers to the degree of identity between two sequences over a comparison window (i.e., on a nucleotide-to-nucleotide basis for nucleic acids or an amino acid-to-amino acid basis for peptides). The percentage of sequence identity is calculated by comparing the two best aligned sequences over the comparison window, determining the number of positions at which the identical nucleic acid bases or amino acid residues appear in the two sequences, and then dividing the number of matching positions by the total number of positions in the comparison window (i.e., the window size). The result is multiplied by 100 to obtain the percentage of sequence identity.

[0103] It should be noted that sequence identity is always calculated over the entire length of the reference sequence. In view of this, the term "comparison window" as used herein refers to a conceptual segment of contiguous nucleotide or amino acid positions in which a nucleotide or amino acid sequence can be compared to a reference sequence, and wherein the portion of the nucleotide or amino acid sequence in the comparison window may include additions or deletions (i.e., gaps), while the reference sequence does not include additions or deletions for optimal alignment of the two sequences.

[0104] Optimal alignment of sequences for comparison can be performed by the local homology algorithm of Smith and Waterman, Adv. Appl. Math. 1981, 2:482, by the alignment algorithm of Needleman and Wunsch, J. Mol. Biol. 1970, 48:443, by the search similarity method of Pearson and Lipman, Nat. Acad. Sci. USA 1988, 85:2444, or by computer implementations of these algorithms (including, but not limited to, CLUSTAL in the PC / Gene program of Intelligentics, Mountain View, Calif.; GAP, BESTFIT, BLAST, FASTA or TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group (GCG), 575 Science Dr., Madison, Wis., USA). The CLUSAL program is well described in Higgins and Sharp, Gene 1988, 73: 237-244; Higgins and Sharp, CABIOS 1989, 5: 151-153; Corpet et al., Nucleic Acids Res. 1988, 16: 10881-10890; Huang et al., Computer Applications in the Biosciences 1992, 8: 155-165; and Pearson et al., Methods in Molecular Biology 1994, 24: 307-331. Alignments are also typically performed by inspection and manual alignment.

[0105] It should be noted that the peptide sequences described herein only define the primary structure of the peptide, i.e., the amino acid sequence, and do not include any information about disulfide bonds (-SS-) that may be present in the peptide. Disulfide bonds are produced by the oxidative folding of two different thiols (-SH) present in the peptide. The peptides described herein contain at least eight different thiols (i.e., each of the eight cysteine ​​residues contains a thiol), and theoretically can form 0, 1, 2, 3, 4 or more intramolecular disulfide bonds. However, it should be understood that the peptides in the context of the entire application include natural disulfide bonds (i.e., Cys I-IV, Cys II-VI, Cys III-VII, and Cys V-VIII), as shown in Table 1.

[0106] Table 1 and Table 2 describe preferred embodiments of ginseng peptides and ginseng peptide-like peptides according to the present application.

[0107] Table 1. Ginseng peptide amino acid sequence

[0108]

[0109] Each bold "G" represents a glycine residue introduced by Fmoc-(Dmb)Gly-OH during solid phase peptide synthesis.

[0110] PG: Panax ginseng; PN: Panax notoginseng; PQ: American ginseng.

[0111] Disulfide linkages: Cys I-IV, Cys II-VI, Cys III-VII, and Cys V-VIII.

[0112] Table 2. Amino acid sequences of preferred ginseng peptide-like peptides

[0113]

[0114]

[0115] Solid-phase peptide synthesis, or 'SPPS', refers to the direct chemical synthesis of peptides in which an insoluble support serves as an anchor for a growing peptide chain, which is typically built one amino acid at a time. The free N-terminal amine of the solid-phase linked peptide is coupled to an N-protected amino acid unit. This unit is then deprotected, revealing a new N-terminal amine to which additional amino acid units can be attached. The general principle of SPPS is one of repeated cycles of coupling-washing-deprotection-washing steps, typically adding one amino acid at a time, until a peptide of the desired sequence and length is synthesized. As will be appreciated by those skilled in the art, in principle, N-protected peptides rather than single amino acids can be coupled to the growing chain in one or more extension cycles. The present invention also includes methods in which one or more larger N-protected peptides or oligopeptides, typically having a length of up to 20 amino acids, preferably up to 10 amino acids, more preferably up to 5 amino acids, and more preferably up to 4 amino acids, are added to the growing chain. In a particularly preferred embodiment, a method as defined herein is provided in which step a) comprises stepwise coupling of amino acids, dipeptides and / or tripeptides, preferably amino acids and / or dipeptides, to the growing peptide chain. In the most preferred embodiment of the present invention, step a) comprises the stepwise coupling of single amino acids or building blocks (eg amino acid pairs) to the growing peptide chain.

[0116] Preferably, according to the present invention, the growing peptide is anchored to the resin via the terminal carboxyl group. However, it is also envisaged and perhaps even preferred, to use certain linkers that allow anchoring of the growing peptide chain via side chain residues.

[0117] The solid support of SPPS is typically a solid, insoluble support material. For the purposes of the present invention, such a solid support comprises a site for anchoring the first amino acid (or peptide). These functional sites for anchoring the peptide are referred to as linkers. If desired, other linker moieties may be used, such as, for example, more specialized, for example, more acid-labile, linkers that can be grafted onto a first integral linker on the preformed solid support, which is often referred to as a "handle." Polymeric organic resin supports are the most common type of solid support material and typically comprise highly solvated polymers with uniformly distributed functional groups. Examples include polystyrene (PS); polyacrylamide (PA); polyethylene glycol (PEG); PEG-polystyrene (PEG-PS) or PEG-polyacrylamide (PEG-PA); and other PEG-based supports. The present invention is not particularly limited to the solid support material. 2-Chlorotrityl chloride resin, Wang resin (4-benzyloxybenzyl alcohol resin), and PAM resin (4-hydroxymethyl-phenylacetamidomethyl) are particularly suitable solid support materials for use in the methods of the present invention. Other suitable examples include, but are not limited to, PEG-HMPB (PEG functionalized with 4-(4-hydroxymethyl-3-methoxyphenoxy)butyric acid for cross-linking); Rink amide resin (4-(2',4'-dimethoxyphenyl-Fmoc-aminomethyl-phenoxy resin); and Merrifield resin (a copolymer of styrene and chloromethylstyrene cross-linked with divinylbenzene). In addition to being chemically inert and able to withstand the conditions of synthesis, the solid support material should meet several requirements: the solid support particles preferably have a regular and uniform size, high mechanical strength, easy to filter, and easy solvent access to allow the reagents to penetrate and the peptide chains to expand within their microstructure. The resins used in the present invention typically have a standard mesh size of about 50-500 mesh, more preferably 100-400 mesh.

[0118] As described above, the method of the present invention relates to the so-called 'Fmoc SPPS' method, in which Fmoc (fluorenylmethoxycarbonyl) N-protected amino acids and peptides are added to the growing chain. Fmoc protection in solid support peptide synthesis has significant advantages because its removal involves very mild alkaline conditions (e.g., piperidine solution), so that it does not interfere with the acid-labile linker between the peptide and the resin. Fmoc N-protected amino acids are commercially available. In addition, reactions to produce Fmoc N-protected amino acids or peptides are common knowledge to those skilled in the art.

[0119] In suitable cases, each incoming amino acid added to the growing peptide chain is also preferably protected with a side chain protecting group, which is typically acid-labile. Protective groups suitable for this purpose are well known in the art. Common carboxyl protecting groups for glutamine and aspartic acid are, for example, Mpe, O-1-adamantyl, O-benzyl, or even simple alkyl esters can be used, although less common. For convenience, tert-butyl is usually and preferably used. Tyrosine can usually be protected by a protecting group, such as tert-butyl ether or Z- or more preferably 2-bromo-Z-ester. Trityl alcohol protecting groups can be used equally, such as 2-chloro-trityl or 4-methoxy or 4,4'-methoxy-trityl. Preferably, trityl or tert-butyl (tBu) protecting groups are used, most preferably tBu protecting groups, i.e., tyrosyl side chains are modified to tert-butyl ether. The tBu group is effectively removed only under strongly acidic conditions. Suitable arginine protecting groups include 2,2,4,6,7-pentamethylbenzofuranyl-5-sulfonyl (Pbf), adamantyloxy-carbonyl and isobornyl-oxy-carbonyl, 2,2,5,7,8-pentamethylbenzodihydropyran-6-sulfonyl (Pmc), 4-methoxy-2,3,6-trimethylbenzenesulfonyl (Mtr) and its 4-tert-butyl-2,3,5,6-tetramethyl homologue (Tart) or Boc, which are cleaved only under strongly acidic conditions. Preferably, Pbf, Pmc, Mtr are used, most preferably Pbf. When the side chain is fully deprotected under strongly acidic conditions, no side alkylation of the deprotected tyrosine is observed with Pmc, Mtr and Pbf, usually in aqueous media. Serine and threonine can usually be protected, for example, by tert-butyl or trityl groups, most preferably tert-butyl. Other protection schemes are also possible, such as with a benzyl group, but are less preferred because they ultimately require removal under less than ideal conditions. Similar considerations apply to the protection of lysine; typically and preferably, Lys is protected with Boc. Tryptophan is not necessarily protected during solid-phase synthesis, but Boc protection is generally envisioned. With respect to side-chain protecting groups, the above descriptions are valid for both natural L-amino acids and their D-homologs.

[0120] Therefore, in various embodiments, step (a) includes the following steps:

[0121] (i) deprotecting a first amino acid attached to a solid support by removing a protective chemical group from the first amino acid;

[0122] (ii) activating a chemical group on the second amino acid to prepare the second amino acid to be coupled to the first amino acid;

[0123] (iii) coupling the activated second amino acid to the deprotected first amino acid to form a peptide consisting of the first and second amino acids; and

[0124] (iv) Successively deprotecting and coupling multiple amino acids into the growing peptide chain until a ginseng peptide or a ginseng peptide-like peptide is synthesized.

[0125] The abundance of glycine and cysteine ​​residues in ginseng peptide sequences often poses a synthetic challenge to their chemical synthesis, especially at the C-terminus. Attempts to synthesize ginseng peptides stepwise using solid-phase methods have failed because the C-terminal fragments form aggregates, hindering the success of the synthesis. The methods described herein address these challenges. In particular, a strategically selected glycine residue, namely the glycine residue at position 24 of SEQ ID NO: 1, is alkylated with a reversible protecting group to prevent aggregation during synthesis. Fmoc-(Dmb)Gly-OH is used to add a glycine residue at this position, while Fmoc-Gly-OH can be used to introduce glycine residues at other positions.

[0126] Coupling agents for Fmoc peptide synthesis are well known in the art. Coupling agents can be mixed anhydrides (e.g., propanephosphonic anhydride) or other acylating agents, such as activated esters or acid halides (e.g., isobutyl-chloroformate or 'ICBF'), or they can be carbodiimides (e.g., 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide, diisopropylcarbodiimide, dicyclohexylcarbodiimide), activated benzotriazine derivatives (e.g., 3-(diethoxyphosphoryloxy)-1,2,3-benzotriazine-4(3H)-one or 'DEPBT') or urea or phosphonium salt derivatives of benzotriazole. In view of optimal yield, short reaction time, and prevention of racemization during chain extension, coupling agents are preferably selected from urea and phosphonium salts of benzotriazole that can activate the free carboxylic acid functional group, and the reaction is carried out in the presence of a base. Suitable and also preferred examples of such uronium or phosphorus coupling salts are, for example, HBTU (O-1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, BOP (benzotriazol-1-yl-oxy-tris-(dimethylamino)-phosphonium hexafluorophosphate), PyBOP (benzotriazol-1-yl-oxy-tripyrrolidinylphosphonium hexafluorophosphate), PyAOP, HCTU (O-(1H-6-chloro-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate), TCTU (O-1H-6-chloro-

[0014] In some embodiments, the present invention comprises the following:

[0014] tetramethyluronium tetrafluoroborate (HAPyU) (O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate),

[0015] tetramethyluronium tetrafluoroborate (HAPyU) (O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate),

[0015] tetramethyluronium tetrafluoroborate (HAPyU) (O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate ...).

[0127] In order to couple Fmoc amino acids to peptides, the carboxyl group is usually activated. This is important for accelerating the reaction. There are two main types of activated groups: carbodiimides and triazole alcohols. When using highly activated urea or phosphonium salt coupling agents, it is particularly preferred to use these activated coupling additives. The most preferred coupling additives are N-hydroxy-benzotriazole derivatives (or 1-hydroxy-benzotriazole derivatives) or N-hydroxy-benzotriazine derivatives. Suitable examples include N-hydroxy-succinimide, N-hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine (HOOBt), 1-hydroxy-7-azabenzotriazole (HOAt) and N-hydroxy-benzotriazole (HOBT). In the most preferred embodiment, N-hydroxy-benzotriazine derivatives are particularly preferred, and the coupling agent additive is hydroxy-3,4-dihydro-4-oxo-1,2,3-benzotriazine. The most common carbodiimides are dicyclohexylcarbodiimide (DCC) and diisopropylcarbodiimide (DIC).

[0128] Activation of Fmoc amino acids is typically carried out in the presence of an alkaline agent. Preferably, the alkaline agent is a weak base having a conjugate acid pKa value of pKa 7.5-15, more preferably pKa 7.5-10, and the base is preferably a tertiary amine or a hindered amine. Such and further preferred embodiments are Hunig bases (N,N-diisopropylethylamine; DIPEA), N,N'-dialkylaniline, 2,4,6-trialkylpyridine, 2,6-trialkylpyridine or N-alkyl-morpholine, wherein the alkyl group is a linear or branched C1-C4 alkyl group, more preferably N-methylmorpholine (NMM) or collidine (2,4,6-trimethylpyridine), and most preferably collidine.

[0129] The amounts of the various reactants in the coupling reaction can and will vary widely. The reagents are typically used in large excess to accelerate the reaction and drive it to completion. Typically, the molar ratio of the amount of solid support to the amount of Fmoc-amino acid is about 1:1 to 1:10. In one embodiment, the molar ratio of the amount of solid support to the amount of fmoc amino acid to the amount of activating compound is about 1:4. The reaction conditions of the coupling step, such as reaction time, temperature, and pH, may vary without departing from the scope of the present invention. The coupling temperature is typically in the range of 15-30°C, particularly when using phosphine or urea coupling agents. Typically, the coupling is carried out at a temperature of about 20-25°C.

[0130] In various embodiments, the method comprises accelerating at least one of the deprotection, activation, and coupling steps by applying microwave energy.

[0131] The microwave energy applied to the contents of the reaction vessel during the deprotection, activation, coupling, and cleavage steps significantly reduces the time required to complete these reactions. The method of applying the microwave energy can be adjusted by the microwave source to provide the fastest reaction time while accumulating the least amount of heat, thereby allowing more microwave energy to be applied without causing heat-related degradation of the reaction contents. This method may include, but is not limited to, increasing the microwave energy by a large amount over a short period of time.

[0132] The method may include cooling the reaction vessel and thereby cooling its contents during and between the application of microwave energy up to and including the final cleavage step. The cooling mechanism of the method operates during the amino acid elongation cycle, where the term "cycle" as used herein refers to the deprotection, activation, and coupling necessary to connect one amino acid to another. The cooling system may also be operated during and between the application of microwave energy in a given cycle to keep the overall temperature of the reaction contents low. The cooling system may also be operated while the intact peptide is being separated from the resin. Alternatively, the desired control over the reaction process may be provided by controlling the power rather than strictly controlling the temperature.

[0133] It should be noted that the amino acid sequence of any one of SEQ ID NOs: 1-64 described above only defines the primary structure of the ginseng peptide or ginseng peptide-like peptide, i.e., the amino acid sequence, and does not include any information on disulfide bonds (-SS-) that may exist in the peptide.

[0134] Disulfide bonds are generated by the oxidative folding of two different thiols (-SH) present in the peptide. The peptides described herein contain eight different thiols (i.e., each of the eight cysteine ​​residues contains a thiol), and thus can form 0, 1, 2, 3, or 4 intramolecular disulfide bonds. The number of possible disulfide bonding patterns (cysteine ​​pairings) increases rapidly with the number of bound cysteines.

[0135] To form native intracellular disulfide bonds, the synthetic process described herein is followed by oxidative folding of the synthetic peptide. Oxidative folding of a peptide or protein refers to the simultaneous formation of one or more native disulfide bonds in its reduced form into an oxidized folded form that shares the same disulfide linkages as the native molecule. Disulfides in peptides or proteins stabilize their structure and maintain their biological activity. Many bioactive peptides are rich in cysteine, containing 2-5 disulfide bonds. However, oxidative folding or refolding of synthetic or recombinant peptides or proteins, particularly those rich in cysteine, is invariably performed in an aqueous buffer solution in the presence of a pair of reducing and oxidizing reagents, using a disulfide exchange reaction to promote correct disulfide bond formation. However, oxidative folding in aqueous solution is a limiting step in its preparation due to the unpredictability of isomers and dead-end products. Chemoselective disulfide methods, which selectively form each disulfide pair stepwise, can achieve correctly paired disulfide bonds, but the process is laborious and generally yields low yields. Methods for oxidative folding of cysteine-rich peptides include air oxidation, use of strong oxidants, or reduction / oxidation of glutathione, and are always in aqueous media at alkaline pH, which can be referred to as aqueous oxidative folding. In the present invention, ultra-fast oxidative folding of peptides under non-aqueous conditions has been achieved and carried out in organic solvents (organic oxidative folding). Compared to aqueous oxidative folding, organic oxidative folding is significantly faster.

[0136] In various embodiments, the organic oxidative folding comprises folding the ginseng peptide or ginseng peptide-like peptide in an organic solvent (preferably DMSO and / or isopropanol) comprising cysteamine and / or morpholine, for example, in a folding buffer comprising 10% (v / v) DMSO, 84.36% (v / v) isopropanol, 5% (v / v) morpholine and 0.64% (v / v) cysteamine (10 M).

[0137] In various embodiments, the organic oxidative folding is performed at 4°C.

[0138] It is believed that the organooxidative folding methods described herein are capable of forming native disulfide bonds of cysteine-rich peptides within minutes, for example, within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 35, 40, 45, 50, 55 or 59 minutes, preferably within 5 minutes, which is significantly faster than conventional methods known in the art (e.g., aqueous oxidative folding).

[0139] In various embodiments, the method comprises purifying the folded ginseng peptide or ginseng peptide-like peptide or a salt thereof, preferably by RP-HPLC.

[0140] Without wishing to be bound by any particular theory, it is believed that the ginseng peptide or ginseng peptide-like peptide prepared by the method described herein has four natural disulfide bonds, as shown in Table 1. The prepared ginseng peptide or ginseng peptide-like peptide is identical to the natural peptide and is functionally indistinguishable.

[0141] It should be noted that the methods of solid phase peptide synthesis and organic oxidative folding described herein can also be used to prepare other cysteine-rich peptides. These uses are also within the scope of this application.

[0142] In a second aspect, the present invention relates to a method for recombinantly preparing a ginseng peptide or a ginseng peptide analogous peptide or a pharmaceutically acceptable salt thereof, wherein the ginseng peptide or ginseng peptide analogous peptide has (i) an amino acid sequence as shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, preferably at least 75%, even more preferably at least 85%, and most preferably at least 95% sequence identity with the entire sequence of the peptide (i), wherein the method comprises the following steps:

[0143] (a) providing a host cell comprising a polynucleotide, wherein the polynucleotide encodes a polypeptide comprising a maltose binding protein having the amino acid sequence of SEQ ID NO: 65, an enterokinase cleavage sequence having the amino acid sequence of SEQ ID NO: 65, and a ginseng peptide or a ginseng peptide-like peptide or a salt thereof;

[0144] (b) cultivating the host cell in a growth medium under conditions permitting production of the polypeptide, and recovering the polypeptide from the medium; and

[0145] (c) cleaving the polypeptide using enterokinase to produce a ginseng peptide or a ginseng peptide-like peptide or a salt thereof.

[0146] The polypeptide can be recombinantly expressed in a host cell or a cell-free system. Any known and well-established expression system and recombinant cell culture technology can be used to produce the polypeptide. The polypeptide can also be produced in a host cell of a transgenic organism, such as a goat or a plant.

[0147] The term "host cell" as used herein refers to any cell typically used for expression, i.e., transcription and translation of a polynucleotide that produces a polypeptide of interest. Specifically, the term "host cell" refers to prokaryotes, lower eukaryotes, plants, insect cells, or mammalian cell culture systems. Host cells include, but are not limited to, bacterial, microbial, plant, or animal cells, such as Escherichia coli, Bacillus subtilis, Saccharomyces cerevisiae, Pichia pastoris, or CHO cells.

[0148] For the recombinant production of polypeptide, the polynucleotide encoding the polypeptide is usually separated and inserted into a reproducible vector, such as a plasmid, for further cloning (amplification) or expression. In a plurality of embodiments, the polynucleotide encoding the polypeptide according to the present invention is included in a vector such as a plasmid. The term "vector" as used herein refers to a polynucleotide capable of transporting another nucleic acid connected thereto. In one embodiment, the vector is a "plasmid", which refers to a circular double-stranded DNA loop, to which additional DNA fragments can be connected. In another embodiment, the vector is a viral vector, to which additional DNA fragments can be connected to the viral genome. Vectors disclosed herein can autonomously replicate in the host cell introducing them (for example, bacterial vectors and free mammalian vectors with bacterial origins of replication), or can be integrated into the genome of the host cell after being introduced into the host cell, thereby replicating together with the host genome (for example, non-free mammalian vectors).

[0149] When recombinant techniques are used, the polypeptide can be produced intracellularly, in the periplasmic space, or directly secreted into the culture medium. If the polypeptide is produced intracellularly, as a first step, the particulate debris of the host cells or lysed fragments is removed, for example, by centrifugation or ultrafiltration. Carter et al., Bio / Technology 1992;10:163-167 describe methods for isolating polypeptides secreted into the periplasmic space of E. coli cells. The polypeptide can be obtained directly in a soluble and folded state or recovered as inclusion bodies and then renatured in vitro. Another option is to use specific host strains with an oxidizing intracellular environment, which allows disulfide bonds to form in the cytosol (Venturi M, Seifert C, Hunte CJ Mol Biol 2002;315,1-8).

[0150] In various embodiments, the polypeptide has an amino acid sequence as set forth in any one of SEQ ID NOs: 67-130.

[0151] Table 3. Amino acid sequences shown in SEQ ID NOs: 65-80

[0152]

[0153]

[0154]

[0155]

[0156]

[0157]

[0158] The recombinantly produced polypeptide is further cleaved by enterokinase immediately after the C-terminus of the enterokinase cleavage site (Asp-Asp-Asp-Asp-Lys, SEQ ID NO: 66), allowing the ginseng peptide or ginseng peptide-like peptide to be released for further purification.

[0159] In various embodiments, the method further comprises purifying the recombinantly produced polypeptide prior to enterokinase cleavage, preferably by purification on an amylose resin.

[0160] The polypeptide produced by the cells can be purified using any conventional purification technique, such as by gel electrophoresis, dialysis, affinity chromatography, or preferably by anion exchange chromatography and / or reverse phase chromatography. The choice of purification method used for a particular polypeptide of the invention is within the knowledge of those of ordinary skill in the art.

[0161] Without wishing to be bound by any particular theory, the ginseng peptides or ginseng peptide analogs produced recombinantly using the methods described herein have native disulfide bonds such that organooxidative folding of the ginseng peptides or ginseng peptide analogs is not required.

[0162] Due to their high sequence similarity, it is believed that the ginseng peptides or ginseng peptide-like peptides described herein have similar biological functions.

[0163] In addition, it should be understood that the above method can also be used to prepare polypeptides comprising, consisting essentially of, or consisting of the ginseng peptides or ginseng peptide-like peptides of the present invention. It can also be used in the applications described below. Such preparation methods and uses of these polypeptides are also within the scope of this application. The ginseng peptides or ginseng peptide-like peptides and polypeptides described herein are preferably substantially free of impurities, but may still contain foreign compounds or impurities from many sources, such as unreacted starting materials, by-products, degradation products, and residual components of host cells.

[0164] It should also be understood that enriched fractions obtained by chromatography, size exclusion or purification-related methods to enrich peptides with a MW of 2-5 kDa from ginseng plants or plants containing ginseng peptide-related compounds from natural sources, and their use in nutritional food, pharmaceutical or cosmetic applications as described below are also within the scope of this application.

[0165] In a third aspect, the present invention relates to the use of a ginseng peptide or a ginseng peptide-like peptide or a pharmaceutically acceptable salt thereof, or an enriched fraction obtained from a ginseng plant or a plant containing a ginseng peptide or a ginseng peptide-like peptide by chromatography, size exclusion, or purification-related methods. The ginseng peptide or ginseng peptide-like peptide has (i) an amino acid sequence as shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, preferably at least 75%, even more preferably at least 85%, and most preferably at least 95% sequence identity to the entire sequence of the peptide in (i), as an α1-adrenergic receptor antagonist and vasodilator.

[0166] In a fourth aspect, the present invention relates to the use of a ginseng peptide or a ginseng peptide-like peptide or a pharmaceutically acceptable salt thereof, or an enriched fraction obtained from a ginseng plant or a plant containing a ginseng peptide or a ginseng peptide-like peptide by chromatography, size exclusion, or purification-related methods. The ginseng peptide or ginseng peptide-like peptide has (i) an amino acid sequence as shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, preferably at least 75%, even more preferably at least 85%, and most preferably at least 95% sequence identity with the entire sequence of the peptide in (i), as a nitric oxide promoter.

[0167] In a fifth aspect, the present invention relates to the use of a ginseng peptide or a ginseng peptide-like peptide or a pharmaceutically acceptable salt thereof, or an enriched fraction obtained from a ginseng plant or a plant containing a ginseng peptide or a ginseng peptide-like peptide by chromatography, size exclusion or purification-related methods, wherein the ginseng peptide or ginseng peptide-like peptide has (i) an amino acid sequence as shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, preferably at least 75%, even more preferably at least 85%, and most preferably at least 95% sequence identity with the entire sequence of the peptide in (i), as an antithrombotic agent.

[0168] In a sixth aspect, the present invention relates to the use of a ginseng peptide or a ginseng peptide-like peptide, or a pharmaceutically acceptable salt thereof, or an enriched fraction obtained from a ginseng plant or a plant containing a ginseng peptide or a ginseng peptide-like peptide by chromatography, size exclusion, or purification-related methods, wherein the ginseng peptide or ginseng peptide-like peptide has (i) an amino acid sequence as shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, preferably at least 75%, even more preferably at least 85%, and most preferably at least 95% sequence identity to the entire sequence of the peptide in (i), as an anti-atherosclerotic agent.

[0169] In a seventh aspect, the present invention relates to the use of a ginseng peptide or a ginseng peptide-like peptide or a pharmaceutically acceptable salt thereof, or an enriched fraction obtained from a ginseng plant or a plant containing a ginseng peptide or a ginseng peptide-like peptide by chromatography, size exclusion or purification-related methods. The ginseng peptide or ginseng peptide-like peptide has (i) an amino acid sequence as shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, preferably at least 75%, even more preferably at least 85%, and most preferably at least 95% sequence identity with the entire sequence of the peptide in (i), as a protective agent against doxorubicin-induced cardiotoxicity.

[0170] In an eighth aspect, the present invention relates to the use of ginseng peptides or ginseng peptide-like peptides or pharmaceutically acceptable salts thereof, or enriched fractions obtained from ginseng plants or plants containing ginseng peptides or ginseng peptide-like peptides by chromatography, size exclusion, or purification-related methods. The ginseng peptides or ginseng peptide-like peptides have (i) an amino acid sequence as shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, preferably at least 75%, even more preferably at least 85%, and most preferably at least 95% sequence identity with the entire sequence of the peptide in (i), as anti-aging and physiological regulators.

[0171] In a ninth aspect, the present invention relates to the use of a ginseng peptide or a ginseng peptide-like peptide or a pharmaceutically acceptable salt thereof, or an enriched fraction obtained from a ginseng plant or a plant containing a ginseng peptide or a ginseng peptide-like peptide by chromatography, size exclusion, or purification-related methods. The ginseng peptide or ginseng peptide-like peptide has (i) an amino acid sequence as shown in any one of SEQ ID NOs: 1-64; or (ii) an amino acid sequence having at least 65%, preferably at least 75%, even more preferably at least 85%, and most preferably at least 95% sequence identity with the entire sequence of the peptide in (i), as a nutraceutical, health product, or cosmetic ingredient.

[0172] As used herein, the term "nutraceutical" refers to a substance used to supplement the diet and provide nutrients, such as, for example, vitamins, minerals, fiber, fatty acids, or amino acids, which may be missing from the diet or not consumed in sufficient amounts. As used herein, the term "nutraceutical" includes animal and / or human foods and food supplements, food fortifiers, dietary supplements, functional (and medical) foods, and nutritional supplements. As used herein, the term "cosmetic ingredient" refers to any agent that may be included in a cosmetic formulation for cosmetic use, such as skin conditioning agents and anti-aging agents.

[0173] In various embodiments of the third to ninth aspects of the present invention, whether commercially obtained, isolated from natural sources, or preferably synthesized or recombinantly prepared by the methods described herein, ginseng peptides or ginseng peptide analogs or their salts can be used as bioactive agents in vitro. In various embodiments, they can be administered alone or in combination with one or more other agents (simultaneously, sequentially or individually) to a subject in need (e.g., a human or animal) in an effective amount for the treatment or prevention of conditions, diseases or disorders that are considered suitable. These conditions, diseases or disorders include, but are not limited to, hypertension, ischemic heart disease, thrombosis, atherosclerosis, erectile dysfunction, stroke, myocardial infarction, heart failure, cancer, aging and aging-related diseases.

[0174] Therefore, ginseng peptides or ginseng peptide analogs or their salts can be formulated into compositions that further comprise a pharmaceutically acceptable carrier. The term "pharmaceutically acceptable carrier" as used herein refers to a pharmaceutically acceptable material, composition, or carrier, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, that is involved in carrying or transporting the peptide from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable," i.e., compatible with the other ingredients of the formulation and harmless to the patient. Some examples of materials that can serve as pharmaceutically acceptable carriers include: sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; powdered gum tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; glycols such as propylene glycol; polyols such as glycerol, sorbitol, mannitol, and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; sterile distilled water; pyrogen-free water; isotonic saline; Ringer's solution; ethanol; pH buffered solutions; polyesters, polycarbonates, or polyanhydrides; and other nontoxic, compatible substances used in pharmaceutical formulations. See Remington: The Science and Practice of Pharmacy, 19th Ed. (Easton, Pa.: Mack Publishing Co., 1995), which discloses typical carriers and general methods for preparing pharmaceutical formulations.

[0175] Those skilled in the art will also recognize that appropriate formulation depends on the route of administration selected for a particular application, and that the appropriate route and manner of administering the peptides of the present invention to a subject should be determined on a case-by-case basis.

[0176] The compositions of the present invention can be administered by any parenteral or non-parenteral (enteral) route effective for protein or nucleic acid-based drug therapy. Parenteral application methods include, for example, intradermal, subcutaneous, intramuscular, intratracheal, intranasal, intravitreal or intravenous injection and infusion techniques, for example, in the form of injectable solutions, infusions or tinctures, as well as aerosol devices and inhalers, for example, in the form of aerosol mixtures, sprays or powders. An overview of pulmonary administration, i.e., by inhalation of aerosols (which can also be used for intranasal administration) or intratracheal instillation, is given, for example, in Patton et al., Proc Amer Thoracic Soc 2004; Vol. 1 pages 338-344. Non-parenteral administration methods, for example, oral, such as in the form of pills, tablets, capsules, solutions or suspensions, or rectal, such as in the form of suppositories. The peptides of the present invention can be administered systemically or topically as desired in formulations containing conventional non-toxic pharmaceutically acceptable excipients or carriers, additives and excipients.

[0177] In one embodiment of the invention, the drug is administered parenterally to a mammal, in particular a human. Corresponding methods of administration include, but are not limited to, for example, intradermal, subcutaneous, intramuscular, intratracheal or intravenous injection and infusion techniques, for example, in the form of injection solutions, infusions or tinctures, as well as aerosol devices and inhalants, for example, in the form of aerosol mixtures, sprays or powders.

[0178] The dosage of the peptides of the present invention may vary widely to achieve the desired prophylactic or therapeutic response. For example, it will depend on the half-life of the peptide in vivo. In addition, the optimal dosage will depend on the biodistribution of the peptide, the mode of administration, the severity of the disease / disorder being treated, and the medical condition of the patient. If desired, the peptides may also be administered in a sustained release formulation, such as a liposomal dispersion or a hydrogel-based polymer microsphere, such as PolyActive TM or OctoDEX TM (See Bos et al., Business Briefing: Pharmatech 2003: 1-6.) Other available sustained-release formulations are, for example, PLGA-based polymers (PR Pharmaceuticals), PLA-PEG-based hydrogels (Medincell), and PEA-based polymers (Medivas).

[0179] Therefore, the peptides of the present invention can be made into compositions using pharmaceutically acceptable ingredients and established preparation methods (Gennaro, AL and Gennaro, AR (2000) Remington: The Science and Practice of Pharmacy, 20th Ed., Lippincott Williams & Wilkins, Philadelphia, PA). To prepare pharmaceutical compositions, pharmaceutically inert inorganic or organic excipients can be used. To prepare, for example, pills, powders, gelatin capsules or suppositories, for example, lactose, talc, stearic acid and its salts, fats, waxes, solid or liquid polyols, natural and hardened oils can be used. Suitable excipients for producing solutions, suspensions, emulsions, aerosol mixtures or powders for reconstitution into solutions or aerosol mixtures prior to use include water, alcohols, glycerol, polyols and suitable mixtures thereof, and vegetable oils.

[0180] In some embodiments, ginseng peptides or ginseng peptide-like peptides or salts thereof can be included in any cosmetic composition known in the art to provide a topical skin regeneration and / or anti-aging composition.

[0181] The formulations can be sterilized by various methods, including filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions that can be dissolved or dispersed in sterile water or other sterile medium prior to use.

[0182] Compositions and methods for therapeutic or cosmetic applications of the above-mentioned ginseng peptides or ginseng peptide-like peptides and compositions are also within the scope of the present application.

[0183] The present invention is further illustrated by the following examples. However, it should be understood that the present invention is not limited to the exemplary embodiments.

[0184] Example

[0185] Materials and Methods

[0186] General procedure for solid-phase peptide synthesis via Fmoc-chemistry

[0187] For peptide-hydrazide reactions, 2-chlorotrityl chloride resin was first swollen in anhydrous dichloromethane (DCM) for a period of time, and 5% hydrazine was added directly to anhydrous dimethylformamide (DMF) solution. After 0.5 h, the resin was washed with DCM (3x), DMF (3x), and DCM (3x). The peptide was then assembled on the hydrazine-trityl resin using a typical Fmoc SPPS protocol. All amino acids were used in 4 equivalents of resin and preactivated with 4 equivalents of benzotriazol-1-yl-oxytripyrrolidinophosphine hexafluorophosphate (PyBop) and 8 equivalents of N,N-diisopropylethylamine (DIEA). After coupling the amino acids for 1 to 2 h, the resin was washed with DCM (3x), DMF (3x), and DCM (3x). Between each amino acid coupling step, sequential α-amino deprotection was performed in 20% piperidine in DMF (5 min, 10 min). Finally, the peptide-hydrazide was released from the resin by using a cleavage reagent: a mixture of 90% TFA, 5% EDT, 2.5% TIS, and 2.5% water. After precipitation from diethyl ether, the crude peptide-hydrazide was purified by preparative high performance liquid chromatography (HPLC), and the molecular weight was determined by electrospray ionization mass spectrometry (ESI-MS).

[0188] For cysteinyl peptides, first, 2 equivalents of Fmoc-Cys(Trt)-OH were dissolved in anhydrous DCM (with a small amount of anhydrous DMF) and added to a swollen 2-chlorotrityl chloride resin with 5 equivalents of DIEA (corresponding to the amino acid). After 1 hour of reaction, the resin was washed with DCM (3x), DMF (3x), and DCM (3x). To block any remaining active trityl groups, the resin was reacted with methanol for 15 minutes. Once the cysteine ​​residue was attached to the resin, the same steps as above were followed for amino acid coupling, α-amino deprotection, and final peptide cleavage.

[0189] Microwave-assisted automated peptide synthesis

[0190] Microwave-assisted peptide syntheses were performed on a CEM Microwave Peptide Synthesizer Liberty 1 using 0.1 mmol and 0.25 mmol reagents according to the manual. Fmoc-(Dmb)Gly-OH was used for the C-terminal portion of the peptide instead of Fmoc-Gly-OH. Fmoc deprotection was performed in 20% piperidine / DMF containing 0.1 M 1-hydroxybenzotriazole (HOBt). Coupling of the Fmoc / tBu-protected amino acid was achieved with 5 equivalents of the amino acid activated with PyBop in DMF. The parameters used in the microwave synthesis are shown in the table below.

[0191] Table 6. MW-SPPS parameters used in the synthesis (CEM microwave peptide synthesizer, liberty 1)

[0192]

[0193] After peptide synthesis, the peptide was cleaved in a mixture of 90% trifluoroacetic acid (TFA), 5% ethanedithiol (EDT), 2.5% triisopropylsilane (TIS) and 2.5% water. The peptide precipitated with ether was then used directly in the folding reaction.

[0194] Linking of peptide-hydrazide to cysteinyl peptide

[0195] Briefly, Fmoc-peptide hydrazide is first oxidized to form peptide azide by sodium nitrite (5 equivalents of peptide) in 0.2M phosphate buffer containing 6M Gdn-HCl, pH 3.0 at -20°C for 20 min. 2-Methylthiosulfonate (MESNa) is added (final concentration is 1%) and the pH is adjusted to 7.0 to form a peptide thioester. Finally, the peptide thioester reacts chemoselectively with the cysteinyl-peptide to generate a natural amide bond at the ligation site to produce the full-length peptide. Fmoc is removed from the ligated full-length peptide by treatment with tris(2-carboxyethyl)phosphine (TCEP) in 20% piperidine for 20 minutes.

[0196] Reduction of peptides to their native form

[0197] For most ginseng peptides and cysteine-rich peptides, folding is performed in 20% DMSO in 0.1 M (NH4HCO3) containing cysteamine / cystamine. The peptide:cysteamine:cystamine ratio is approximately 1:200:10. Depending on the solubility of the peptide, 10% TFE, 5% or 10% IPA may be added. The peptide is dissolved in a very small amount of DMSO and then added to the folding buffer. Folding is allowed to proceed overnight at 4°C. Following folding, the reaction is buffer exchanged and concentrated using a Sek-Pak C18 column. The concentrated folding mixture is purified by HPLC to obtain the pure folded product.

[0198] For organic oxidative folding, the peptide was dissolved in a very small amount of DMSO, added to a folding buffer containing 10% (v / v) DMSO, 84.36% (v / v) isopropanol, 5% (v / v) morpholine, and 0.64% (v / v) cysteamine (10 M), and folded at 4° C. for 5 min. After folding, the reaction was buffer exchanged and concentrated using a Sek-Pak C18 column. The concentrated folding mixture was purified by HPLC to obtain the pure folded product.

[0199] Recombinant expression of ginseng peptide

[0200] Overall strategy for recombinant expression of ginseng peptides

[0201] 1. The targeting sequence was cloned into a vector in which the ginseng peptide was fused to the C-terminus of the periplasmic signal sequence, maltose binding protein (MBP), with a DDDK-cleavable sequence in between (enterokinase can cleave at the C-terminus of DDDK);

[0202] 2. Transform the plasmid into E. coli and screen using agar plates containing ampicillin;

[0203] 3. Pick a single colony and grow it in LB liquid medium containing ampicillin at 37°C with shaking at 200 rpm until the optical density reaches approximately 0.6;

[0204] 4. Induce with 0.1 mM isopropylthiogalactoside (IPTG) at 16°C overnight;

[0205] 5. Load the cell lysate onto an amylose affinity column and elute with maltose; and

[0206] 6. Enterokinase is used to cleave maltose binding protein (MBP);

[0207] 7. Anion exchange and reversed-phase HPLC were used to purify recombinantly expressed ginseng peptides.

[0208] Isolation and purification of ginseng peptides from Panax ginseng, American ginseng, or Panax notoginseng

[0209] Approximately 1 kg of dried roots, leaves, seeds or flowers of Panax ginseng, American ginseng or Panax notoginseng were extracted with 10 liters of water. After filtration, the filtrate was loaded onto a C18 flash column (Grace Davison, US) and eluted with 70% ethanol. The eluted fraction was then loaded onto an SP Sepharose resin column (GE Healthcare, UK), eluted with 1 M NaCl (pH 3.0), and then ultrafiltered (ViVaflow 200, 2000 MWCO hydrostat). Further purification was performed by reverse phase high performance liquid chromatography (RP-HPLC) (Shimadzu, Japan). The eluted fraction was purified by HPLC on a C18 column (250×22 mm, 5 μm, ) (Grace Davison, US) using a linear gradient of mobile phase A (0.05% TFA / H2O) and mobile phase B (0.05% TFA / ACN).

[0210] This invention relates to the synthesis and use of ginseng peptides as peptidogenic adaptogens to extend our healthy lifespan. Peptides act to regulate physiological processes by extending the timeline of cellular and biological aging. In turn, they intervene in age-related diseases and promote active and healthy aging. In particular, ginseng peptides can address cardiovascular disease and frailty, underlying causes of many chronic and age-related conditions, such as cancer, cardiovascular disease, inflammation, stress, and other metabolic disorders. Figure 1 This is a schematic diagram depicting the physiological regulatory effects of ginseng peptides. The synthesis and uses of ginseng peptides will be described in the following sections:

[0211] 1. Ginseng peptide production

[0212] 2. Ginseng peptide as an α1-adrenergic receptor antagonist and vasodilator in rat aortic rings

[0213] 3. Ginseng peptide as a nitric oxide booster

[0214] 4. Ginseng peptides as antithrombotic agents

[0215] 5. Ginseng peptides as anti-atherosclerotic agents

[0216] 6. Ginseng peptides as a protective agent against doxorubicin-induced cardiotoxicity

[0217] 7. Ginseng peptides as anti-aging and physiological regulators

[0218] Example 1: Ginseng peptide production

[0219] The abundance of glycine and cysteine ​​in ginseng peptide sequences presents synthetic challenges for their synthesis, particularly at the C-terminus. Attempts to synthesize ginseng peptides via stepwise synthesis using solid-phase methods have failed due to the formation of aggregates in the C-terminal fragments, hindering successful synthesis. Therefore, this invention describes a stepwise solid-phase synthesis strategy for chemically synthesizing ginseng peptides to overcome these synthetic challenges. Specifically, strategically selected Gly residues were alkylated with reversible protecting groups to prevent aggregation, allowing the successful synthesis of ginseng peptide TP1 as a representative example.

[0220] An organic oxidative folding system for forming disulfide bonds has been invented. Using the present invention, native disulfide bonds of cysteine-rich peptides are formed within minutes (e.g., within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, or 59 minutes) rather than hours, accelerating oxidative folding a thousand-fold. The present invention also improves reaction yields and can be performed at high peptide concentrations without observed peptide precipitation. Furthermore, all reagents used in the method are inexpensive, making the synthesis economically advantageous. Thus, it can be applied to the large-scale production of cysteine-rich peptides.

[0221] Recombinant expression of ginseng peptides is advantageous because the use of chemicals used to produce ginseng peptides will be eliminated. In addition, the expressed ginseng peptides produced using the recombinant expression platform will be in their folded state, eliminating the need for a second step of oxidative folding.

[0222] Technical description of the invention

[0223] i. Table 1 shows the amino acid sequences of ginseng peptides.

[0224] ii. Figure 2 A schematic flow chart for the chemical synthesis of ginseng peptides is shown.

[0225] iii. Figure 3 The oxidative folding strategy for the synthetic ginseng peptide TP1 is shown.

[0226] iv. Figure 4 、 5 , 6 showed that the synthetic ginseng peptides were identical to natural ginseng peptides and functionally indistinguishable from natural ginseng peptides obtained from ginseng.

[0227] v. Figure 7-11 The recombinant expression scheme of ginseng peptides is shown.

[0228] Oxidative folding involves a process for forming disulfide bonds in peptides and proteins in which a reduced or partially oxidized peptide is fully oxidized in a non-aqueous system using an organic solvent and compatible organic reducing and oxidizing (redox) reagents.

[0229] The basic principle of the present invention is based on the observation that oxidative folding is mediated by a thiol-disulfide exchange reaction, which is an SN2 reaction (bimolecular nucleophilic substitution reaction). This reaction occurs more readily in organic solvents than in aqueous conditions where the attacking thiol nucleophile is dissolved by water. Eliminating water under oxidative folding conditions should accelerate the thiol-disulfide exchange reaction, thereby accelerating the oxidation process.

[0230] In the present invention, four main components are introduced: an organic base, an organic solvent, a structure-enhancing co-solvent, and a redox agent. An organic base, such as pyridine, imidazole, or morpholine, is used to provide suitable alkalinity for disulfide formation, while the organic solvent provides an environment in which the thiol-disulfide exchange reaction is one thousand times faster than under aqueous conditions, which is the most common approach in the literature. In addition, the structure-enhancing co-solvent and the redox agent ensure the correct disulfide pairing of the folded product. Using a structure-enhancing solvent such as trifluoroethanol (TFE), the native secondary structure is preferentially formed, thereby allowing the natural pairing of cysteine ​​to approach the formation of the correct disulfide connection. Using a reducing agent compatible with an organic solvent such as cysteamine and the oxidant dimethyl sulfoxide (DMSO), the incorrect disulfide connection can be reorganized into the correct disulfide connection through the thiol-disulfide exchange reaction.

[0231] The reduced peptide can be synthesized via solid-phase / liquid-phase synthesis or recombinant expression. It is then purified and lyophilized. The reduced peptide is dissolved in pure DMSO, which also serves as a mild oxidizing agent, and diluted with an organic solvent to a final concentration of 0.1 mM to 1 mM. Subsequently, an organic base and reducing agent are added. If the reducing agent is insoluble in the organic solvent, the reducing agent can be dissolved in a small amount of water. The final volume of water should preferably not exceed 20% of the total mixture.

[0232] The above method was used to fold the cyclic peptide kalata B1 (kB1) as an example. Fully reduced kB1 was dissolved in DMSO as the starting material. 2-Propanol was added as the organic solvent to dilute the peptide. An organic base, including pyridine, imidazole, or morpholine, and the reducing agent cysteamine were then added. Each condition contained 100 μM pf reduced kB1, 10% (v / v) DMSO, and 100 mM cysteamine, along with varying concentrations of solvent and base.

[0233] · Figure 12 RP-HPLC and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) spectra of native and reduced kB1 are shown.

[0234] Table 4 shows the oxidative folding conditions of kB1 with different solvent combinations.

[0235] · Figure 13 The reversed-phase ultra-performance liquid chromatography (RP-UPLC) profile of kB1 oxidative folding is shown, illustrating the effects of different bases.

[0236] · Figure 14 Shown are the RP-UPLC profiles of the oxidative folding of kB1 and the effects of cysteamine and DMSO as redox agents.

[0237] · Figure 15Shown are RP-HPLC profiles of the oxidative folding of kB1 using different thiols as reducing agents.

[0238] · Figure 16 The 1H nuclear magnetic resonance ( 1H NMR) spectra of native and synthetic kB1 prepared by organooxidative folding were compared.

[0239] Table 4. Oxidative folding conditions of kB1 at different solvent concentrations

[0240]

[0241] *The yield was calculated based on the RP-HPLC spectrum of the reaction for 1 h.

[0242] Example 2. Ginseng peptide as an α1 adrenergic receptor antagonist and vasodilator in rat aortic rings

[0243] The present invention shows that ginseng peptide TP1 has vasodilatory properties.

[0244] Plant peptides and proteins are generally underexplored as bioactive ingredients in medicinal plants. Unlike other peptides and proteins, cysteine-rich peptides are stabilized by multiple intramolecular disulfide bonds, making them extremely stable to heat, acid, and enzymatic degradation. This study demonstrates that the cysteine-rich peptide, panax notoginseng peptide TP1, has eight cysteine ​​residues (four stable disulfide bonds) and a unique pseudocyclic structure, making it stable to heat, acid, serum, and proteolytic degradation.

[0245] Cysteine-rich peptides are highly cross-linked via intramolecular disulfide bonds. This forces the bulky hydrophobic side chains to be exposed outward, making the molecular surface more lipophilic. Furthermore, slow exchange with heavy water (D2O) indicates that the hydrogen bonds of ginseng peptides are intramolecular rather than exposed outward. These features allow ginseng peptides to be desolvated from water. Therefore, the unique properties of ginseng peptides may improve inherent cellular permeability and intestinal absorption, making them orally active.

[0246] Technical Description

[0247] Figure 17 A schematic diagram of the purification of ginseng peptides from ginseng plants is shown. All ginseng peptides, including TP1 (referred to herein as native ginseng peptide TP1), were purified to a high degree of homogeneity through solvent-solvent separation, ion exchange, size exclusion, and reversed-phase high-pressure liquid chromatography. The yield of ginseng peptides from different plant tissues varied >10-fold, with seeds and flowers producing the highest yields (0.2-0.4%) and roots and leaves producing the lowest (0.01-0.03%). Thus, nearly 400 mg of ginseng peptides can be obtained from 1 kg of dried flowers or seeds.

[0248] Table 1 shows the amino acid sequences of ginseng peptides.

[0249] Figure 18 and 19 Ginseng peptides TP1, TP3, and TP8 have been shown to alleviate phenylephrine-induced, but not KCl-induced, contraction in aortic rings. To examine the vasomotor response of ginseng peptide TP1, isolated thoracic aortas were precontracted with KCl (30 mM) or the selective α1-adrenergic receptor agonist, phenylephrine (0.1 μM). Isometric tension was recorded as a measure of aortic ring contraction. In vitro results showed that ginseng peptide TP1 inhibited phenylephrine-induced contraction in a dose-dependent manner (p < 0.05), but not in the KCl-treated group.

[0250] Table 5 shows that ginseng peptide TP1 is metabolically stable.

[0251] Figure 20 The slow exchange of D2O was shown, indicating that the extensive hydrogen bond network in ginseng peptide TP1 confers structural stability.

[0252] Figure 21 Shown are the TP1 sequence, its secondary structure, the overall layout of synthetic and natural TP1, the CPK model of the TP1 hydrophobic surface, and the 3D structure of TP.

[0253] Table 5 Metabolic stability of ginseng peptide TP1

[0254]

[0255] Example 3. Ginseng peptide as a nitric oxide promoter

[0256] The present invention shows that ginseng peptide TP1 induces nitric oxide synthesis. Compared with the main components of ginsenosides in ginseng, such as Rg1 and Rb1, ginseng peptide TP1 is more effective than ginsenosides Rg1 and Rb1 in nitric oxide synthesis.

[0257] Plant peptides and proteins are generally underexplored as bioactive ingredients in medicinal plants. Unlike other peptides and proteins, cysteine-rich peptides are stabilized by multiple intramolecular disulfide bonds, making them extremely stable to heat, acid, and enzymatic degradation. This study demonstrates that the cysteine-rich peptide, panax notoginseng peptide TP1, has eight cysteine ​​residues (four stable disulfide bonds) and a unique pseudocyclic structure, making it stable to heat, acid, serum, and proteolytic degradation.

[0258] Ginseng peptides are cysteine-rich peptides that are highly cross-linked via intramolecular disulfide bonds. Because ginseng peptides are 31 amino acids long and contain four disulfide bonds, they have an inside-out arrangement, with the inner core connected by four disulfide bonds. This structural arrangement forces the bulky hydrophobic side chains to be exposed outward, making the molecular surface more lipophilic. In fact, 3D NMR analysis reveals that the surface of ginseng peptides is typically composed of hydrophobic amino acids. Furthermore, as demonstrated by the slow exchange of DO in NMR studies, ginseng peptides are highly compact, with a large network of stable internal hydrogen bonds. This internal hydrogen bonding not only stabilizes the ginseng peptide structure but also desolvates the peptide from the water to which it is hydrogen-bonded externally. Taken together, these unique properties of ginseng peptides improve their cellular permeability and intestinal absorption, making them bioavailable. In other words, ginseng peptides possess the stability and oral bioavailability of small molecules, but possess a larger footprint to increase their target specificity and reduce the potential for off-target side effects.

[0259] Technical description of the invention

[0260] Table 1 shows the amino acid sequences of ginseng peptides.

[0261] Figure 22 Shown are profiles of ginseng peptides from the three most commonly used ginseng species: Panax ginseng, American ginseng, and Panax notoginseng.

[0262] Figure 23 The tissue distribution of ginseng peptides in ginseng is shown.

[0263] Figure 24 De novo sequencing of the ginseng peptide TP1 is shown.

[0264] Figure 25 The disulfide linkages of ginseng peptide TP1 are shown.

[0265] Figure 26 Transcripts encoding ginsenosides are shown for all three commonly used ginseng species: Panax ginseng, American ginseng, and Panax notoginseng.

[0266] Figure 27 Ginseng peptide TP1 was shown to increase cellular NO production in human endothelial cells (HUVEC-CS). In comparison, ginseng peptide TP1 showed three times the potency and NO release of ginsenosides Rb1 and Rg1. Ginseng peptides TP1, TP3, TP8, and synthetic TP1 showed similar cellular NO release.

[0267] Figure 28 The results show that ginseng peptide TP1 induces the accumulation of phosphorylated endothelial nitric oxide synthase (p-eNOS). 1 μM ginseng peptide TP1 induces the accumulation of p-eNOS within about 30 minutes.

[0268] Figure 29It was shown that PI3K / Akt signaling is involved in nitric oxide formation induced by ginseng peptide TP1.

[0269] Table 5 shows that ginseng peptide TP1 is metabolically stable.

[0270] Figure 30 The slow exchange of D2O was shown, indicating that the extensive hydrogen bond network in ginseng peptide TP1 confers structural stability.

[0271] Figure 31 The results showed that ginseng peptide TP1 has no cytotoxicity to cells, but has hemolytic activity against erythrocytes. It also showed that ginseng peptide TP1 has no immunogenicity.

[0272] Example 4. Ginseng peptides as antithrombotic agents

[0273] This study demonstrates that ginseng peptide TP1 has an antagonistic effect against P2y12 activation. Compared to the major ginsenosides in ginseng, ginseng peptide TP1 is more effective than ginsenosides Rg1 and Rb1 in antagonizing P2y12 activation. Ginseng peptide TP1 also exhibits antiplatelet aggregation effects in vivo.

[0274] Plant peptides and proteins are generally underexplored as bioactive ingredients in medicinal plants. Unlike other peptides and proteins, cysteine-rich peptides are stabilized by multiple intramolecular disulfide bonds, making them extremely stable to heat, acid, and enzymatic degradation. This study demonstrates that the cysteine-rich peptide, panax notoginseng peptide TP1, has eight cysteine ​​residues (four stable disulfide bonds) and a unique pseudocyclic structure, making it stable to heat, acid, serum, and proteolytic degradation.

[0275] Cysteine-rich peptides are highly cross-linked via intramolecular disulfide bonds. This forces the bulky, hydrophobic side chains to be exposed outward, making the molecular surface more lipophilic. Furthermore, the slow exchange of D2O indicates that the hydrogen bonds of ginseng peptides are intramolecular rather than outwardly exposed. These features allow ginseng peptides to be desolvated from water. Therefore, the unique properties of ginseng peptides may improve intrinsic cellular permeability and intestinal absorption, making them orally active.

[0276] Technical description of the invention

[0277] Table 1 shows the amino acid sequences of ginseng peptides.

[0278] Figure 32 The results showed that ginsenoside TP1 antagonized P2y12 activation and was more effective than ginsenosides Rb1 and Rg1.

[0279] Figure 34 Ginseng peptide TP1 was shown to inhibit platelet aggregation in vivo.

[0280] Table 4 shows that ginseng peptide TP1 is stable to heat, acid, proteolysis and serum-mediated degradation.

[0281] Figure 33 The slow exchange of D2O was shown, indicating that the extensive hydrogen bond network in ginseng peptide TP1 confers structural stability.

[0282] Example 5. Ginseng peptides as anti-atherosclerotic agents

[0283] The present invention shows that human ginseng peptide TP1 is an endothelial cell selective adhesion molecule binder that antagonizes monocyte adhesion and may be helpful in the treatment of atherosclerosis. It is five times more potent than the known RGD-derived adhesion inhibitor.

[0284] Plant peptides and proteins are generally underexplored as bioactive ingredients in medicinal plants. Unlike other peptides and proteins, cysteine-rich peptides are stabilized by multiple intramolecular disulfide bonds, making them extremely stable to heat, acid, and enzymatic degradation. This study demonstrates that the cysteine-rich peptide, panax notoginseng peptide TP1, has eight cysteine ​​residues (four stable disulfide bonds) and a unique pseudocyclic structure, making it stable to heat, acid, serum, and proteolytic degradation.

[0285] Cysteine-rich peptides are highly cross-linked via intramolecular disulfide bonds. This forces the bulky, hydrophobic side chains to be exposed outward, making the molecular surface more lipophilic. Furthermore, the slow exchange of D2O indicates that the hydrogen bonds of ginseng peptides are intramolecular rather than outwardly exposed. These features allow ginseng peptides to be desolvated from water. Therefore, the unique properties of ginseng peptides may improve intrinsic cellular permeability and intestinal absorption, making them orally active.

[0286] The present invention shows that several ginseng peptides bind to a heparin affinity column, which can be used to purify ginseng peptides from raw materials.

[0287] A novel heparin-binding sequence derived from a ginseng peptide was identified that can be used as a new affinity tag for recombinant expression.

[0288] Technical description of the invention

[0289] Table 1 shows the amino acid sequences of ginseng peptides.

[0290] Figure 35 The results showed that ginseng peptide TP1 exhibited protein-protein interaction with endothelial cell selective adhesion molecule (ESAM), which is involved in the interaction between monocytes and endothelial cells.

[0291] Figure 36 Ginseng peptide TP1 was shown to antagonize monocyte adhesion with a potency 5-fold greater than known adhesion inhibitors.

[0292] Figure 37 Several ginseng peptides were shown to be heparin binders and heparin affinity chromatography could be used for affinity purification.

[0293] Figure 38 We show the identification of a novel heparin-binding sequence from the human ginseng peptide TP1. For recombinant protein expression, this novel sequence can be inserted into the N- or C-terminus to aid heparin affinity purification. To promote efficient cell binding, heparin-binding motifs are known to bind to heparan sulfate proteoglycans, which form a major part of the extracellular matrix of cells. This novel heparin-binding motif can be conjugated to other materials to promote their attachment to the cell surface. Therefore, this novel heparin-binding sequence can be used in peptide design and engineering to promote efficient cell binding and as an affinity purification tag for recombinant expression.

[0294] Example 6. Ginseng peptides as protective agents against doxorubicin-induced cardiotoxicity

[0295] Currently, four strategies have been used to prevent doxorubicin-induced cardiotoxicity, but these strategies still have inevitable drawbacks.

[0296] The first strategy is to adjust the dosing schedule of doxorubicin. Some studies have shown that prolonged infusion of doxorubicin can reduce cardiotoxicity compared to bolus administration (LEGHA, SS et al., Annals of Internal Medicine, 1982. 96(2): p.133-139.). However, randomized trials have shown that infusion administration preferentially increases the tendency of patients to develop metastases (Casper, ES et al., Cancer, 1991. 68(6): p.1221-1229.).

[0297] The second approach is to modify the structure of doxorubicin and synthesize analogs. The most commonly used structural analogs, epirubicin and mitoxantrone, have lower cardiotoxicity than doxorubicin, but their chemotherapeutic efficacy is lower than that of doxorubicin (Lehenbauer Ludke, AR. et al., Canadian Journal of Physiology and Pharmacology, 2009. 87(10): p.756-763.).

[0298] The third strategy is to develop a pharmaceutical formulation of doxorubicin to control the peak concentration after administration. Liposomal encapsulation of doxorubicin can prolong the half-life of doxorubicin and increase its accumulation in tumor tissue rats rather than the heart due to its small size, but there is still the possibility of cardiac dysfunction at high cumulative doses (Abraham, SA. et al., Methods in Enzymology, 2005. 391: p.71-97.).

[0299] A final approach to reduce the risk of doxorubicin-induced cardiotoxicity is to combine it with cardioprotective agents or compounds. However, these interfere with the therapeutic potential of doxorubicin or may induce secondary malignancies in cancer patients, including dexrazoxane (Tebbi, CK. et al., Journal of Clinical Oncology, 2007. 25(5): p. 493-500), N-acetylcysteine ​​(Myers, C. et al., Semin Oncol, 1983. 10(Suppl 1): p. 53-55), GSH, coenzyme Q10, vitamin A, and α-tocopherol (Legha, SS. et al., Annals of the New York Academy of Sciences, 1982. 393(1): p. 411-417.).

[0300] Our preliminary results here demonstrate that ginseng peptides attenuate doxorubicin-induced cardiotoxicity in zebrafish models and rat cardiomyocytes. Furthermore, ginseng peptides do not interfere with the anticancer activity of doxorubicin during combination therapy in breast cancer cells.

[0301] Ginseng peptides are a new class of cysteine-rich peptides because they contain 31-33 amino acids, have 8 cysteine ​​residues, and resemble a pseudocyclic cysteine ​​knot structure, which is highly resistant to thermal, acidic, and enzymatic degradation. In addition, the pharmacokinetic characteristics of ginseng peptides in mice have shown that they are nontoxic, orally bioavailable, and relatively stable in the blood. These advantages enhance the potential of ginseng peptides as very promising adjunctive cardioprotective agents during chemotherapy.

[0302] Technical description of the invention

[0303] The present invention provides a method for preventing doxorubicin-induced cardiotoxicity by administering doxorubicin in combination with ginseng peptides.

[0304] (1) Cardioprotective effects of ginseng peptides in zebrafish

[0305] In the present invention, the zebrafish transgenic line Tg(cmlc2:gCaMP) (Chi, NC et al., PLoS Biol, 2008. 6(5): p.e109.), which expresses calcium-sensitive green fluorescent protein (GFP) in cardiomyocytes, was used to visualize and evaluate cardiac function in zebrafish embryos.

[0306] No side effects of ginseng peptides were found in zebrafish even when administered at high concentrations. The main side effects of doxorubicin-induced cardiotoxicity in zebrafish embryos include (1) decreased heart rate, (2) decreased ventricular contractility, and (3) triggering of pericardial edema. Addition of ginseng peptides to doxorubicin-treated zebrafish embryos restored the heart rate to near normal levels and reduced the size of the pericardial edema ( Figure 39 and 40 ).

[0307] To evaluate the cardiac function of zebrafish, the ejection fraction (EF) was determined by measuring the ventricular volume at the end of systole and diastole. EF was significantly decreased after doxorubicin treatment, but significantly increased and almost returned to normal after treatment with the combination containing ginseng peptides ( Figure 41 ), which demonstrated that ginseng peptides have a significant cardioprotective effect on doxorubicin-induced cardiotoxicity in zebrafish.

[0308] To determine whether ginseng peptides can attenuate doxorubicin-induced cardiotoxicity in cardiomyocytes, the cell viability after drug treatment was measured by MTT assay. The results showed that ginseng peptides did not exhibit significant toxicity in cardiomyocytes even at high concentrations and enhanced cardiomyocyte growth compared to ginsenosides Rg1, Rb1, and Re, the main components of ginseng. Figure 42 ).

[0309] After 24 h of co-treatment with doxorubicin containing ginseng peptide, the viability of H9c2 cells was increased by approximately 20% compared with that of doxorubicin alone ( Figure 43 However, ginsenosides Rg1, Rb1, and Re did not have any protective effect on cardiomyocytes during doxorubicin treatment.

[0310] (2) No interference with the anti-cancer effect on breast cancer cells

[0311] Next, we investigated whether ginseng peptides could reduce the anticancer effect of doxorubicin on breast tumor cells. The cell viability of MDA-MB-231 cells (human breast cancer cells) was not enhanced after co-treatment with doxorubicin containing ginseng peptides ( Figure 44 ). Ginseng peptides only play a protective role on cardiomyocytes and do not interfere with the therapeutic effect of doxorubicin on tumor cells.

[0312] (3) Pharmacokinetics of ginseng peptide in mice

[0313] Pharmacokinetic characteristics of ginseng peptide in mice ( Figure 45 ) showed that they are orally bioavailable and relatively stable in the blood. No discomfort was observed in mice after treatment with ginseng peptides, and no deaths occurred during the dosing period or one month after administration. These advantages provide strong evidence for the development of ginseng peptides as therapeutic agents for clinical use.

[0314] Example 7. Ginseng peptides as anti-aging and physiological regulators

[0315] Most anti-aging agents are generally classified as antioxidants, which reduce oxidative stress and protect cells from unwanted aging-related processes. In the present invention, human ginseng peptide TP1 is disclosed as an anti-aging agent that directly prevents telomere shortening by reducing the levels of telomere repeat binding factor 2 (TERF2).

[0316] Unlike antioxidant anti-aging compounds, ginseng peptide TP1 not only prevents aging caused by oxidative stress, but also slows down the entire aging process by blocking the telomere shortening process and promoting adaptation to stress.

[0317] Different from traditional peptide drugs, ginseng peptide TP1 has been demonstrated to be a potential orally active agent due to its good stability in both the gastrointestinal tract and serum.

[0318] Technical description of the invention

[0319] To understand the function of ginseng peptide TP1 at the molecular level, HUVEC-CS cells were treated with 1 μM TP1 for 30 min. After termination of treatment, cells were collected by scraping and washed with ice-cold PBS. The cells were lysed in urea lysis buffer (8 M urea in 25 mM tetraethylammonium bromide (TEAB), supplemented with a protease inhibitor cocktail). 200 μg of protein were digested each time using the in-solution trypsin digestion technique. The generated tryptic peptides were labeled with TMT reagent, separated by reverse phase fractionation at high pH (pH ~ 8), and analyzed using a Q-Exactive mass spectrometer coupled to nanotechnology-high performance liquid chromatography (nano-HPLC). Protein identification and quantification were performed using the UniProtKB human protein database and the mascot search engine (version 2.4.1). We identified a total of 5058 proteins using a peptide list and a 1% FDR (false discovery rate) cutoff. The control condition was used as the denominator for relative protein quantification based on TMT. Cutoff values ​​of 0.85 and 1.17 were used as cutoff levels for changes in protein abundance ( Figure 46 a). Using this method, 62 and 113 proteins were identified as up-regulated and down-regulated in cells treated with ginseng peptide ( Figure 46 b). Regulated proteins are classified according to their biological functions ( Figure 46 c).

[0320] Interestingly, after 30 min of TP1 treatment, the level of telomere repeat binding factor 2 (TERF2) decreased significantly ( Figure 46d) TP1 reduces TERF2, slowing telomere shortening and preventing cellular aging. Therefore, TP1 specifically prevents aging in vascular cells and maintains blood vessel flexibility. It also reduces other aging-related issues.

[0321] Figure 47 The study showed the effects of ginseng peptide TP1 on the proteome of hypoxic endothelial cells. Ginseng peptide TP1 induced the unfolded protein response pathway in hypoxic endothelial cells. It also reduced apoptosis signaling pathways and cell adhesion pathways.

[0322] Figures 48-53 It was shown that ginseng peptide TP1 promotes the adaptation of endothelial cells to hypoxic stress.

[0323] Figure 54 .Ginseng peptides reduce unfolded proteins in cardiomyocytes, vascular smooth muscle cells, and myocytes.

[0324] Figure 55 .Ginseng peptides reduce the production of reactive oxygen species in hypoxic endothelial cells.

[0325] Figure 56 .Ginseng peptides increase nitric oxide production in hypoxic endothelial cells.

[0326] The invention is generally and generally described herein. Each of the narrower species and subgeneric groupings falling within the general disclosure also forms part of the invention. This includes the general description of the invention, with any subject matter removed from it by a limitation or negative limitation, regardless of whether the removed material is explicitly listed herein. Other embodiments are within the appended claims. In addition, when features or aspects of the invention are described in terms of Markush groups, those skilled in the art will recognize that the invention is also described in terms of any individual member or subgroup of members of the Markush group.

[0327] It will be readily appreciated by those skilled in the art that the present invention is well adapted to achieve the objects and obtain the purposes and advantages indicated, as well as those inherent therein. Furthermore, it will be apparent to those skilled in the art that changes, substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. The compositions, methods, procedures, treatments, molecules and specific compounds described herein are exemplary of preferred embodiments and are not intended to limit the scope of the invention. Variations and other uses thereof will occur to those skilled in the art, which are encompassed within the spirit of the invention and limited by the scope of the claims. The listing or discussion of a previously published document in this specification should not be considered an admission that the document is part of the prior art or is common general knowledge.

[0328] The invention illustratively described herein may suitably be practiced in the absence of any element or elements, limitation or limitations not specifically disclosed herein. Thus, for example, the terms "comprise," "include," "includes," "including," "etc." should be interpreted broadly and without limitation. Thus, the word "comprise" and variations thereof (such as "comprises" or "comprising") should be understood to imply the inclusion of the stated integer or groups of integers but not the exclusion of any other integer or groups of integers. Furthermore, the terms and expressions employed herein are used in a manner descriptive and not restrictive, and the use of such terms and expressions is not intended to exclude any equivalents of the features shown and described, or portions thereof, and it should be recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the invention has been specifically disclosed by way of exemplary embodiments and optional features, modifications and variations of the invention disclosed herein may be employed by those skilled in the art and should be considered to be within the scope of the invention.

[0329] The contents of all documents and patent publications cited herein are incorporated by reference in their entirety. Sequence Listing <110> Nanyang Technological University <120> Preparation and utilization of ginseng peptides and ginseng peptide-like peptides <130> P112990 <150> Singapore Patent Application No. 10201609388X <151> 2016-11-09 <160> 200 <170> PatentIn version 3.5 <210> 1 <211> 31 <212> PRT <213> Panax ginseng <400> 1 Cys Lys Ser Gly Gly Ala Trp Cys Gly Phe Asp Pro His Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 20 25 30 <210> 2 <211> 31 <212> PRT <213> Panax ginseng <400> 2 Cys Lys Ser Ser Gly Ala Trp Cys Gly Phe Asp Pro His Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 20 25 30 <210> 3 <211> 31 <212> PRT <213> Panax ginseng <400> 3 Cys Lys Ser Ala Gly Thr Trp Cys Gly Phe Asp Pro His Gly Cys Cys 1 5 10 15 Gly Ser Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Val Ser Cys 20 25 30 <210> 4 <211> 33 <212> PRT <213> Panax ginseng <400> 4 Cys Leu Lys Asn Gly Glu Phe Cys Trp Gly Asp Pro Ser Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Ile Ile Pro Gly Val Cys Tyr Gly Thr Gly 20 25 30 Cys <210> 5 <211> 31 <212> PRT <213> Panax ginseng <400> 5 Cys Lys Ser Ser Gly Ala Trp Cys Gly Phe Asp Pro His Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Asp Cys 20 25 30 <210> 6 <211> 31 <212> PRT <213> Panax ginseng <400> 6 Cys Ile Pro Gly Gly Gly Phe Cys Met Phe Glu Pro Leu Ser Cys Cys 1 5 10 15 Val Asn Cys Gly Cys Ile Leu Val Pro Gly Val Cys Tyr Cys Gly 20 25 30 <210> 7 <211> 31 <212> PRT <213> Panax ginseng <400> 7 Cys Lys Ser Gly Gly Thr Trp Cys Gly Phe Asp Pro His Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 20 25 30 <210> 8 <211> 31 <212> PRT <213> Panax quinquefolius <400> 8 Cys Ile Ser Ser Gly Gly Trp Cys Gly Phe Asp Leu His Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 20 25 30 <210> 9 <211> 31 <212> PRT <213> Panax quinquefolius <400> 9 Cys Lys Ser Gly Gly Ser Trp Cys Gly Phe Asp Pro His Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 20 25 30 <210> 10 <211> 31 <212> PRT <213> CIFSGGWCGFDLHGCCGNCGCLVGFCYGTGC <400> 10 Cys Ile Phe Ser Gly Gly Trp Cys Gly Phe Asp Leu His Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 20 25 30 <210> 11 <211> 33 <212> PRT <213> Panax quinquefolius <400> 11 Cys Leu Lys Asn Gly Gln Phe Cys Trp Gly Asn Pro Ser Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Ile Ile Pro Gly Val Cys Tyr Gly Thr Gly 20 25 30 Cys <210> 12 <211> 31 <212> PRT <213> Panax quinquefolius <400> 12 Cys Ile Pro Gly Gly Gly Phe Cys Met Phe Glu Pro Leu Ser Cys Cys 1 5 10 15 His Asn Cys Gly Cys Leu Leu Val Pro Gly Val Cys Tyr Cys Gly 20 25 30 <210> 13 <211> 31 <212> PRT <213> Panax notoginseng <400> 13 Cys Ile Pro Asn Gly Gly Phe Cys Met Phe Glu Pro Leu Ser Cys Cys 1 5 10 15 Val Asn Cys Gly Cys Ile Leu Val Pro Gly Val Cys Tyr Cys Gly 20 25 30 <210> 14 <211> 32 <212> PRT <213> Panax quinquefolius <400> 14 Cys Leu Lys Val Gly Lys Ile Cys Leu Gly Arg Gly Leu Lys Glu Cys 1 5 10 15 Cys Pro Ser Ala Thr Cys Gly Cys Leu Leu Gly Phe Cys Ile Lys Cys 20 25 30 <210> 15 <211> 34 <212> PRT <213> Angiopteris evecta <400> 15 Cys Ile Pro Lys Gly Gly Trp Cys Leu Phe Asp Ile Met Gly Cys Cys 1 5 10 15 Lys Pro Cys Gly Cys Leu Ala Gly Phe Cys Trp Val Val Gly Asp Asp 20 25 30 Cys Asn <210> 16 <211> 36 <212> PRT <213> Amaranthus retroflexus <400> 16 Cys Val Pro Lys Gly Thr Pro Cys Leu Tyr Lys Pro Glu Pro Cys Cys 1 5 10 15 Gly Ala Asn Cys Phe Cys Asp Thr Ser Ala Tyr Thr Phe Gln Tyr Val 20 25 30 Cys Lys Cys Tyr 35 <210> 17 <211> 35 <212> PRT <213> Agrostis stolonifera <400> 17 Cys Leu Pro Ser Gly Gly Phe Cys Met Phe Arg Pro Thr Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Val Gly Val Cys Tyr Gly Ser Arg 20 25 30 Cys Glu Glu 35 <210> 18 <211> 33 <212> PRT <213> Blasia sp. <400> 18 Cys Leu Lys Asn Gly Glu Phe Cys Trp Gly Asp Pro Ser Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Ile Ile Pro Gly Val Cys Tyr Gly Thr Gly 20 25 30 Cys <210> 19 <211> 30 <212> PRT <213> Bazzania trilobata <400> 19 Cys Leu Asn Gly Gly Gly Tyr Cys Gly Ser Phe Thr Arg Glu Ala Cys 1 5 10 15 Cys Tyr Asn Cys Val Cys Met Met Ala Phe Cys Val Cys Gly 20 25 30 <210> 20 <211> 35 <212> PRT <213> Coffea canephora <400> 20 Cys Ser Pro Phe Gly Lys Pro Cys Arg Tyr Asn Pro Trp Gly Cys Cys 1 5 10 15 Asp Ser Cys Val Cys Val Ala Thr Pro Ala Asp Glu Gly Arg Cys Leu 20 25 30 Gly Asn Cys 35 <210> 21 <211> 33 <212> PRT <213> Daucus carota <400> 21 Cys Leu Pro Asn Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys 1 5 10 15 Gly Ser Cys Gly Cys Leu Tyr Pro Val Gly Val Cys Phe Gly Thr Gly 20 25 30 Cys <210> 22 <211> 33 <212> PRT <213> Daucus carota <400> 22 Cys Tyr Pro Lys Gly His Glu Cys Arg Thr Asp Pro Thr Leu Cys Cys 1 5 10 15 His Asn Cys Gly Cys Ile Met Pro Val Gly Val Cys Phe Gly Ile Asn 20 25 30 Cys <210> 23 <211> 33 <212> PRT <213> Eragrostis curvula <400> 23 Cys Leu Pro Ser Gly Gly Phe Cys Met Phe Arg Pro Lys Asp Cys Cys 1 5 10 15 Gly Ser Cys Gly Cys Leu Tyr Pro Ile Gly Val Cys Phe Gly Ser Ser 20 25 30 Cys <210> 24 <211> 35 <212> PRT <213> Eleusine coracana <400> 24 Cys Ile Pro Met Gly Gly Phe Cys Leu Phe Asn Leu Arg Gly Cys Cys 1 5 10 15 Gly Ser Cys Gly Cys Leu Ala Gly Phe Cys Trp Arg Asp Ala Ser Ser 20 25 30 Cys Asp Leu 35 <210> 25 <211> 35 <212> PRT <213> Eleusine coracana <400> 25 Cys Ile Pro Met Gly Gly Phe Cys Leu Gly Asn Leu Arg Gly Cys Cys 1 5 10 15 Gly Ser Cys Gly Cys Leu Ala Gly Phe Cys Trp Arg Pro Ala Ser Ser 20 25 30 Cys Asp Ser 35 <210> 26 <211> 35 <212> PRT <213> Elymus wawawaiensis <400> 26 Cys Leu Pro Ser Gly Gly Phe Cys Met Phe Arg Pro Lys Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Ile Gly Val Cys Tyr Gly Ser Arg 20 25 30 Cys Glu Glu 35 <210> 27 <211> 37 <212> PRT <213> Gossypium hirsutum <400> 27 Cys Lys Pro Lys Gly Ser Phe Cys Leu Phe Asp Leu Gln Ser Cys Cys 1 5 10 15 Arg Pro Cys Gly Cys Leu Ala Gly Trp Cys Tyr Asn Ile Asp His Asp 20 25 30 Cys Asn Glu Tyr Thr 35 <210> 28 <211> 33 <212> PRT <213> Griselinia littoralis <400> 28 Cys Ile Ser Ser Gly Gly Phe Cys Met Phe Asn Pro Arg Asp Cys Cys 1 5 10 15 Gly Ser Cys Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Ser 20 25 30 Cys <210> 29 <211> 37 <212> PRT <213> Gossypium raimondii <400> 29 Cys Lys Pro Ile Gly Ser Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys 1 5 10 15 Arg Pro Cys Gly Cys Leu Ala Gly Phe Cys Tyr Asn Leu Asp His Asn 20 25 30 Cys Asn Glu Tyr Thr 35 <210> 30 <211> 37 <212> PRT <213> Gossypium raimondii <400> 30 Cys Lys Pro Lys Gly Ser Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys 1 5 10 15 Arg Pro Cys Gly Cys Leu Ala Gly Trp Cys Tyr Asn Tyr Asp His Glu 20 25 30 Cys Asn Glu Tyr Thr 35 <210> 31 <211> 37 <212> PRT <213> Gossypium raimondii <400> 31 Cys Ile Ala Lys Gly Gly Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys 1 5 10 15 Arg Pro Cys Gly Cys Leu Ala Gly Trp Cys Tyr Asn Ile Asp His Asp 20 25 30 Cys Lys Glu Tyr Thr 35 <210> 32 <211> 37 <212> PRT <213> Gossypium raimondii <400> 32 Cys Ile Ala Lys Gly Gly Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys 1 5 10 15 Arg Pro Cys Gly Cys Leu Ala Gly Trp Cys Tyr Asn Ile Asp His Asp 20 25 30 Cys Asn Glu Tyr Ala 35 <210> 33 <211> 37 <212> PRT <213> Gossypium raimondii <400> 33 Cys Ile Ala Lys Gly Gly Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys 1 5 10 15 Arg Pro Cys Gly Cys Leu Ala Gly Trp Cys Tyr Asn Ile Asp His Asp 20 25 30 Cys Asn Glu Tyr Thr 35 <210> 34 <211> 34 <212> PRT <213> Hibiscus cannabinus <400> 34 Cys Ile Pro Lys Gly Gly Trp Cys Leu Phe Asp Ile Met Gly Cys Cys 1 5 10 15 Lys Pro Cys Gly Cys Leu Ala Gly Phe Cys Trp Val Val Gly Asp Asp 20 25 30 Cys Asn <210> 35 <211> 31 <212> PRT <213> Hibbertia grossulariifolia <400> 35 Cys Ser Pro Leu Gly Gly Lys Cys Gly Asp Leu Val Glu Cys Cys Ser 1 5 10 15 Gly Cys Val Cys Ile Trp Pro Thr Tyr Thr Cys Val Gly His Cys 20 25 30 <210> 36 <211> 37 <212> PRT <213> Hedera helix <400> 36 Cys Gln Pro Phe Asp Ala Pro Cys Asp Thr Phe Tyr Gly Phe Tyr Cys 1 5 10 15 Cys Gly Ser Cys Thr Cys Thr Tyr Val Asp Phe Trp His Thr Ser Arg 20 25 30 Cys Thr Gly Ser Cys 35 <210> 37 <211> 33 <212> PRT <213> Heracleum lanatum <400> 37 Cys Leu Pro Ala Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys 1 5 10 15 Gly Thr Cys Gly Cys Leu Tyr Pro Val Gly Val Cys Phe Gly Asn Asp 20 25 30 Cys <210> 38 <211> 33 <212> PRT <213> Lennoa madreporoides <400> 38 Cys Ile Gly Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Val Gly Ile Cys Phe Gly Thr Gly 20 25 30 Cys <210> 39 <211> 30 <212> PRT <213> Microtea madreporoides <400> 39 Cys Leu Asn Gly Gly Gly Tyr Cys Gly Ser Phe Thr Arg Glu Ala Cys 1 5 10 15 Cys Tyr Asn Cys Val Cys Met Met Ala Phe Cys Val Cys Gly 20 25 30 <210> 40 <211> 31 <212> PRT <213> Mollugo nudicaulis <400> 40 Cys Lys Ser Ala Gly Glu Trp Cys Gly Phe Ser Trp Thr Asp Cys Cys 1 5 10 15 Asn Ser Cys Gly Cys Leu Ala Gly Phe Cys Tyr Gly Thr Ser Cys 20 25 30 <210> 41 <211> 35 <212> PRT <213> Myodocarpus sp. <400> 41 Cys Ile Pro Lys Gly Gly Phe Cys Leu Phe Asp Leu Arg Gly Cys Cys 1 5 10 15 Gly Met Cys Gly Cys Leu Ala Gly Val Cys Phe Asn Tyr Asp His Pro 20 25 30 Cys Glu Glu 35 <210> 42 <211> 33 <212> PRT <213> Menyanthes trifoliata <400> 42 Cys Leu Ser Ser Gly Gly Phe Cys Met Phe Arg Pro Asn Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Val Gly Ile Cys Tyr Gly Thr Gly 20 25 30 Cys <210> 43 <211> 35 <212> PRT <213> Oryza sativa <400> 43 Cys Leu Pro Ala Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Val Gly Val Cys Tyr Gly Ser Arg 20 25 30 Cys Glu Glu 35 <210> 44 <211> 35 <212> PRT <213> Pholisma arenarium <400> 44 Cys Leu Pro Ala Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Val Gly Val Cys Tyr Gly Ser Arg 20 25 30 Cys Glu Glu 35 <210> 45 <211> 33 <212> PRT <213> Pholisma arenarium <400> 45 Cys Ile Ser Ala Gly Gly Phe Cys Phe Phe Asp Pro Met Asn Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Val Gly Ile Cys Val Gly Thr Asn 20 25 30 Cys <210> 46 <211> 31 <212> PRT <213> Polyscias fruticosa <400> 46 Cys Ser Pro Leu Gly Gly Lys Cys Gly Asp Leu Val Glu Cys Cys Ser 1 5 10 15 Gly Cys Val Cys Ile Trp Pro Thr Tyr Thr Cys Val Gly His Cys 20 25 30 <210> 47 <211> 35 <212> PRT <213> Polyscias fruticosa <400> 47 Cys Ile Pro Leu Gly Gly Asp Cys Thr Asp Leu Phe Asp Cys Cys Pro 1 5 10 15 Gly Cys Val Cys Ile Ile Thr Asp Leu Thr Cys Asp Gly Asn Cys Phe 20 25 30 Arg Gly Ala 35 <210> 48 <211> 36 <212> PRT <213> Polyscias fruticosa <400> 48 Cys Leu Thr Leu Gly Leu Tyr Cys Gly Gly Gly Ser Gly Glu Cys Cys 1 5 10 15 Ser Gly Cys Leu Cys Val Tyr Pro Thr Leu Thr Cys Arg Gly Asn Cys 20 25 30 Tyr Arg Gly Ala 35 <210> 49 <211> 34 <212> PRT <213> Phyllanthus sp. <400> 49 Cys Ser Asp Pro Gly Gly Tyr Cys Val Pro Phe Phe Gln Gly Cys Cys 1 5 10 15 Asn Asp Cys Ser Cys Leu Asp Leu Gly Val Val Ala Gly Val Cys Val 20 25 30 Cys Ile <210> 50 <211> 33 <212> PRT <213> Populus trichocarpa <400> 50 Cys Ile Ser Ser Gly Gly Trp Cys Phe Thr Gln Pro Lys Asn Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Ile Gly Ile Cys Phe Gly Ser Asp 20 25 30 Cys <210> 51 <211> 33 <212> PRT <213> Populus trichocarpa <400> 51 Cys Ile Ser Ser Gly Gly Trp Cys Phe Pro Asn Pro Lys Asn Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Ile Gly Ile Cys Phe Gly Ser Asp 20 25 30 Cys <210> 52 <211> 33 <212> PRT <213> Populus tremula <400> 52 Cys Ile Ser Ser Gly Gly Phe Cys Phe Thr Gln Pro Met Asn Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Leu Gly Ile Cys Tyr Gly Ser Asp 20 25 30 Cys <210> 53 <211> 33 <212> PRT <213> Salix dasyclados <400> 53 Cys Leu Pro Ser Gly Gly Phe Cys Met Phe Gln Pro Met Asn Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Ile Gly Val Cys Tyr Gly Ser Asn 20 25 30 Cys <210> 54 <211> 33 <212> PRT <213> Theobroma cacao <400> 54 Cys Leu Ser Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 55 <211> 33 <212> PRT <213> Theobroma cacao <400> 55 Cys Leu Ser Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Phe Pro Met Gly Ile Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 56 <211> 33 <212> PRT <213> Theobroma cacao <400> 56 Cys Leu Ser Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Met Gly Phe Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 57 <211> 33 <212> PRT <213> Theobroma cacao <400> 57 Cys Leu Ser Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Leu Gly Phe Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 58 <211> 33 <212> PRT <213> Theobroma cacao <400> 58 Cys Leu Ser Ala Gly Gly Phe Cys Met Phe Asp Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 59 <211> 33 <212> PRT <213> Theobroma cacao <400> 59 Cys Leu Ser Ala Gly Gly Phe Cys Met Phe Ile Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Phe Leu Met Gly Phe Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 60 <211> 33 <212> PRT <213> Theobroma cacao <400> 60 Cys Leu Ser Ala Gly Gly Phe Cys Met Phe Ile Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Phe Pro Met Gly Phe Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 61 <211> 33 <212> PRT <213> Theobroma cacao <400> 61 Cys Leu Ser Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 62 <211> 33 <212> PRT <213> Theobroma cacao <400> 62 Cys Pro Ser Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 63 <211> 33 <212> PRT <213> Theobroma cacao <400> 63 Cys Leu Ser Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Leu Gly Ile Cys Tyr Gly Ser Gly 20 25 30 Cys <210> 64 <211> 35 <212> PRT <213> Triticum aestivum <400> 64 Cys Leu Pro Ala Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Tyr Pro Ala Gly Val Cys Tyr Gly Thr Arg 20 25 30 Cys Glu Glu 35 <210> 65 <211> 408 <212> PRT <213> artificial sequence <220> <223> Maltose-binding protein <400> 65 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leo Gly 405 <210> 66 <211> 5 <212> PRT <213> artificial sequence <220> <223> enterokinase cleavage sequence <400> 66 Asp Asp Asp Asp Lys 1 5 <210> 67 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 67 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Ser 405 410 415 Gly Gly Ala Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 435 440 <210> 68 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 68 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Ser 405 410 415 Ser Gly Ala Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 435 440 <210> 69 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 69 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Ser 405 410 415 Ala Gly Thr Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Ser Cys 420 425 430 Gly Cys Leu Val Gly Phe Cys Tyr Gly Val Ser Cys 435 440 <210> 70 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 70 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Lys 405 410 415 Asn Gly Glu Phe Cys Trp Gly Asp Pro Ser Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Ile Ile Pro Gly Val Cys Tyr Gly Thr Gly Cys 435 440 445 <210> 71 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 71 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Ser 405 410 415 Ser Gly Ala Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Asp Cys 435 440 <210> 72 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 72 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Pro 405 410 415 Gly Gly Gly Phe Cys Met Phe Glu Pro Leu Ser Cys Cys Val Asn Cys 420 425 430 Gly Cys Ile Leu Val Pro Gly Val Cys Tyr Cys Gly 435 440 <210> 73 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 73 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Ser 405 410 415 Gly Gly Thr Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 435 440 <210> 74 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 74 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Ser 405 410 415 Ser Gly Gly Trp Cys Gly Phe Asp Leu His Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 435 440 <210> 75 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 75 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Ser 405 410 415 Gly Gly Ser Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 435 440 <210> 76 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 76 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Phe 405 410 415 Ser Gly Gly Trp Cys Gly Phe Asp Leu His Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 435 440 <210> 77 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 77 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Lys 405 410 415 Asn Gly Gln Phe Cys Trp Gly Asn Pro Ser Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Ile Ile Pro Gly Val Cys Tyr Gly Thr Gly Cys 435 440 445 <210> 78 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 78 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Pro 405 410 415 Gly Gly Gly Phe Cys Met Phe Glu Pro Leu Ser Cys Cys His Asn Cys 420 425 430 Gly Cys Leu Leu Val Pro Gly Val Cys Tyr Cys Gly 435 440 <210> 79 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 79 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Pro 405 410 415 Asn Gly Gly Phe Cys Met Phe Glu Pro Leu Ser Cys Cys Val Asn Cys 420 425 430 Gly Cys Ile Leu Val Pro Gly Val Cys Tyr Cys Gly 435 440 <210> 80 <211> 445 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 80 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Lys 405 410 415 Val Gly Lys Ile Cys Leu Gly Arg Gly Leu Lys Glu Cys Cys Pro Ser 420 425 430 Ala Thr Cys Gly Cys Leu Leu Gly Phe Cys Ile Lys Cys 435 440 445 <210> 81 <211> 447 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 81 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Pro 405 410 415 Lys Gly Gly Trp Cys Leu Phe Asp Ile Met Gly Cys Cys Lys Pro Cys 420 425 430 Gly Cys Leu Ala Gly Phe Cys Trp Val Val Gly Asp Asp Cys Asn 435 440 445 <210> 82 <211> 449 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 82 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Val Pro 405 410 415 Lys Gly Thr Pro Cys Leu Tyr Lys Pro Glu Pro Cys Cys Gly Ala Asn 420 425 430 Cys Phe Cys Asp Thr Ser Ala Tyr Thr Phe Gln Tyr Val Cys Lys Cys 435 440 445 Tyr <210> 83 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 83 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Pro 405 410 415 Ser Gly Gly Phe Cys Met Phe Arg Pro Thr Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Val Gly Val Cys Tyr Gly Ser Arg Cys Glu Glu 435 440 445 <210> 84 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 84 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Lys 405 410 415 Asn Gly Glu Phe Cys Trp Gly Asp Pro Ser Gly Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Ile Ile Pro Gly Val Cys Tyr Gly Thr Gly Cys 435 440 445 <210> 85 <211> 443 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 85 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Asn 405 410 415 Gly Gly Gly Tyr Cys Gly Ser Phe Thr Arg Glu Ala Cys Cys Tyr Asn 420 425 430 Cys Val Cys Met Met Ala Phe Cys Val Cys Gly 435 440 <210> 86 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 86 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ser Pro 405 410 415 Phe Gly Lys Pro Cys Arg Tyr Asn Pro Trp Gly Cys Cys Asp Ser Cys 420 425 430 Val Cys Val Ala Thr Pro Ala Asp Glu Gly Arg Cys Leu Gly Asn Cys 435 440 445 <210> 87 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 87 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Pro 405 410 415 Asn Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys Gly Ser Cys 420 425 430 Gly Cys Leu Tyr Pro Val Gly Val Cys Phe Gly Thr Gly Cys 435 440 445 <210> 88 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 88 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Tyr Pro 405 410 415 Lys Gly His Glu Cys Arg Thr Asp Pro Thr Leu Cys Cys His Asn Cys 420 425 430 Gly Cys Ile Met Pro Val Gly Val Cys Phe Gly Ile Asn Cys 435 440 445 <210> 89 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 89 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Pro 405 410 415 Ser Gly Gly Phe Cys Met Phe Arg Pro Lys Asp Cys Cys Gly Ser Cys 420 425 430 Gly Cys Leu Tyr Pro Ile Gly Val Cys Phe Gly Ser Ser Cys 435 440 445 <210> 90 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 90 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Pro 405 410 415 Met Gly Gly Phe Cys Leu Phe Asn Leu Arg Gly Cys Cys Gly Ser Cys 420 425 430 Gly Cys Leu Ala Gly Phe Cys Trp Arg Asp Ala Ser Ser Cys Asp Leu 435 440 445 <210> 91 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 91 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Pro 405 410 415 Met Gly Gly Phe Cys Leu Gly Asn Leu Arg Gly Cys Cys Gly Ser Cys 420 425 430 Gly Cys Leu Ala Gly Phe Cys Trp Arg Pro Ala Ser Ser Cys Asp Ser 435 440 445 <210> 92 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 92 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Pro 405 410 415 Ser Gly Gly Phe Cys Met Phe Arg Pro Lys Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Ile Gly Val Cys Tyr Gly Ser Arg Cys Glu Glu 435 440 445 <210> 93 <211> 450 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 93 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Pro 405 410 415 Lys Gly Ser Phe Cys Leu Phe Asp Leu Gln Ser Cys Cys Arg Pro Cys 420 425 430 Gly Cys Leu Ala Gly Trp Cys Tyr Asn Ile Asp His Asp Cys Asn Glu 435 440 445 Tyr Thr 450 <210> 94 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 94 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Ser 405 410 415 Ser Gly Gly Phe Cys Met Phe Asn Pro Arg Asp Cys Cys Gly Ser Cys 420 425 430 Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Ser Cys 435 440 445 <210> 95 <211> 450 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 95 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Pro 405 410 415 Ile Gly Ser Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys Arg Pro Cys 420 425 430 Gly Cys Leu Ala Gly Phe Cys Tyr Asn Leu Asp His Asn Cys Asn Glu 435 440 445 Tyr Thr 450 <210> 96 <211> 450 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 96 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Pro 405 410 415 Lys Gly Ser Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys Arg Pro Cys 420 425 430 Gly Cys Leu Ala Gly Trp Cys Tyr Asn Tyr Asp His Glu Cys Asn Glu 435 440 445 Tyr Thr 450 <210> 97 <211> 450 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 97 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Ala 405 410 415 Lys Gly Gly Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys Arg Pro Cys 420 425 430 Gly Cys Leu Ala Gly Trp Cys Tyr Asn Ile Asp His Asp Cys Lys Glu 435 440 445 Tyr Thr 450 <210> 98 <211> 450 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 98 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Ala 405 410 415 Lys Gly Gly Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys Arg Pro Cys 420 425 430 Gly Cys Leu Ala Gly Trp Cys Tyr Asn Ile Asp His Asp Cys Asn Glu 435 440 445 Tyr Ala 450 <210> 99 <211> 450 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 99 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Ala 405 410 415 Lys Gly Gly Phe Cys Leu Phe Asp Leu Thr Ser Cys Cys Arg Pro Cys 420 425 430 Gly Cys Leu Ala Gly Trp Cys Tyr Asn Ile Asp His Asp Cys Asn Glu 435 440 445 Tyr Thr 450 <210> 100 <211> 447 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 100 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Pro 405 410 415 Lys Gly Gly Trp Cys Leu Phe Asp Ile Met Gly Cys Cys Lys Pro Cys 420 425 430 Gly Cys Leu Ala Gly Phe Cys Trp Val Val Gly Asp Asp Cys Asn 435 440 445 <210> 101 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 101 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ser Pro 405 410 415 Leu Gly Gly Lys Cys Gly Asp Leu Val Glu Cys Cys Ser Gly Cys Val 420 425 430 Cys Ile Trp Pro Thr Tyr Thr Cys Val Gly His Cys 435 440 <210> 102 <211> 450 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 102 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Gln Pro 405 410 415 Phe Asp Ala Pro Cys Asp Thr Phe Tyr Gly Phe Tyr Cys Cys Gly Ser 420 425 430 Cys Thr Cys Thr Tyr Val Asp Phe Trp His Thr Ser Arg Cys Thr Gly 435 440 445 Ser Cys 450 <210> 103 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 103 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Pro 405 410 415 Ala Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys Gly Thr Cys 420 425 430 Gly Cys Leu Tyr Pro Val Gly Val Cys Phe Gly Asn Asp Cys 435 440 445 <210> 104 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 104 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Gly 405 410 415 Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Val Gly Ile Cys Phe Gly Thr Gly Cys 435 440 445 <210> 105 <211> 443 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 105 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Asn 405 410 415 Gly Gly Gly Tyr Cys Gly Ser Phe Thr Arg Glu Ala Cys Cys Tyr Asn 420 425 430 Cys Val Cys Met Met Ala Phe Cys Val Cys Gly 435 440 <210> 106 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 106 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Lys Ser 405 410 415 Ala Gly Glu Trp Cys Gly Phe Ser Trp Thr Asp Cys Cys Asn Ser Cys 420 425 430 Gly Cys Leu Ala Gly Phe Cys Tyr Gly Thr Ser Cys 435 440 <210> 107 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 107 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Pro 405 410 415 Lys Gly Gly Phe Cys Leu Phe Asp Leu Arg Gly Cys Cys Gly Met Cys 420 425 430 Gly Cys Leu Ala Gly Val Cys Phe Asn Tyr Asp His Pro Cys Glu Glu 435 440 445 <210> 108 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 108 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ser Gly Gly Phe Cys Met Phe Arg Pro Asn Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Val Gly Ile Cys Tyr Gly Thr Gly Cys 435 440 445 <210> 109 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 109 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Pro 405 410 415 Ala Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Val Gly Val Cys Tyr Gly Ser Arg Cys Glu Glu 435 440 445 <210> 110 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 110 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Pro 405 410 415 Ala Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Val Gly Val Cys Tyr Gly Ser Arg Cys Glu Glu 435 440 445 <210> 111 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 111 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Ser 405 410 415 Ala Gly Gly Phe Cys Phe Phe Asp Pro Met Asn Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Val Gly Ile Cys Val Gly Thr Asn Cys 435 440 445 <210> 112 <211> 444 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 112 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ser Pro 405 410 415 Leu Gly Gly Lys Cys Gly Asp Leu Val Glu Cys Cys Ser Gly Cys Val 420 425 430 Cys Ile Trp Pro Thr Tyr Thr Cys Val Gly His Cys 435 440 <210> 113 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 113 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Pro 405 410 415 Leu Gly Gly Asp Cys Thr Asp Leu Phe Asp Cys Cys Pro Gly Cys Val 420 425 430 Cys Ile Ile Thr Asp Leu Thr Cys Asp Gly Asn Cys Phe Arg Gly Ala 435 440 445 <210> 114 <211> 449 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 114 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Thr 405 410 415 Leu Gly Leu Tyr Cys Gly Gly Gly Ser Gly Glu Cys Cys Ser Gly Cys 420 425 430 Leu Cys Val Tyr Pro Thr Leu Thr Cys Arg Gly Asn Cys Tyr Arg Gly 435 440 445 Ala <210> 115 <211> 447 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 115 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ser Asp 405 410 415 Pro Gly Gly Tyr Cys Val Pro Phe Phe Gln Gly Cys Cys Asn Asp Cys 420 425 430 Ser Cys Leu Asp Leu Gly Val Val Ala Gly Val Cys Val Cys Ile 435 440 445 <210> 116 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 116 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Ser 405 410 415 Ser Gly Gly Trp Cys Phe Thr Gln Pro Lys Asn Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Ile Gly Ile Cys Phe Gly Ser Asp Cys 435 440 445 <210> 117 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 117 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Ser 405 410 415 Ser Gly Gly Trp Cys Phe Pro Asn Pro Lys Asn Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Ile Gly Ile Cys Phe Gly Ser Asp Cys 435 440 445 <210> 118 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 118 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Ile Ser 405 410 415 Ser Gly Gly Phe Cys Phe Thr Gln Pro Met Asn Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Leu Gly Ile Cys Tyr Gly Ser Asp Cys 435 440 445 <210> 119 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 119 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Pro 405 410 415 Ser Gly Gly Phe Cys Met Phe Gln Pro Met Asn Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Ile Gly Val Cys Tyr Gly Ser Asn Cys 435 440 445 <210> 120 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 120 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 121 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 121 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Phe Pro Met Gly Ile Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 122 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 122 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Met Gly Phe Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 123 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 123 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Leu Gly Phe Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 124 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 124 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Asp Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 125 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 125 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Leu Gly Ile Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 126 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 126 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Ile Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Phe Pro Met Gly Phe Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 127 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 127 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 128 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusioni protein <400> 128 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Pro Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Met Gly Ile Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 129 <211> 446 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 129 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Ser 405 410 415 Ala Gly Gly Phe Cys Met Phe Asn Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Leu Gly Ile Cys Tyr Gly Ser Gly Cys 435 440 445 <210> 130 <211> 448 <212> PRT <213> artificial sequence <220> <223> fusion protein <400> 130 Met Lys Ile Lys Thr Gly Ala Arg Ile Leu Ala Leu Ser Ala Leu Thr 1 5 10 15 Thr Met Met Phe Ser Ala Ser Ala Leu Ala Lys Ile Glu Glu Gly Lys 20 25 30 Leu Val Ile Trp Ile Asn Gly Asp Lys Gly Tyr Asn Gly Leu Ala Glu 35 40 45 Val Gly Lys Lys Phe Glu Lys Asp Thr Gly Ile Lys Val Thr Val Glu 50 55 60 His Pro Asp Lys Leu Glu Glu Lys Phe Pro Gln Val Ala Ala Thr Gly 65 70 75 80 Asp Gly Pro Asp Ile Ile Phe Trp Ala His Asp Arg Phe Gly Gly Tyr 85 90 95 Ala Gln Ser Gly Leu Leu Ala Glu Ile Thr Pro Asp Lys Ala Phe Gln 100 105 110 Asp Lys Leu Tyr Pro Phe Thr Trp Asp Ala Val Arg Tyr Asn Gly Lys 115 120 125 Leu Ile Ala Tyr Pro Ile Ala Val Glu Ala Leu Ser Leu Ile Tyr Asn 130 135 140 Lys Asp Leu Leu Pro Asn Pro Pro Lys Thr Trp Glu Glu Ile Pro Ala 145 150 155 160 Leu Asp Lys Glu Leu Lys Ala Lys Gly Lys Ser Ala Leu Met Phe Asn 165 170 175 Leu Gln Glu Pro Tyr Phe Thr Trp Pro Leu Ile Ala Ala Asp Gly Gly 180 185 190 Tyr Ala Phe Lys Tyr Glu Asn Gly Lys Tyr Asp Ile Lys Asp Val Gly 195 200 205 Val Asp Asn Ala Gly Ala Lys Ala Gly Leu Thr Phe Leu Val Asp Leu 210 215 220 Ile Lys Asn Lys His Met Asn Ala Asp Thr Asp Tyr Ser Ile Ala Glu 225 230 235 240 Ala Ala Phe Asn Lys Gly Glu Thr Ala Met Thr Ile Asn Gly Pro Trp 245 250 255 Ala Trp Ser Asn Ile Asp Thr Ser Lys Val Asn Tyr Gly Val Thr Val 260 265 270 Leu Pro Thr Phe Lys Gly Gln Pro Ser Lys Pro Phe Val Gly Val Leu 275 280 285 Ser Ala Gly Ile Asn Ala Ala Ser Pro Asn Lys Glu Leu Ala Lys Glu 290 295 300 Phe Leu Glu Asn Tyr Leu Leu Thr Asp Glu Gly Leu Glu Ala Val Asn 305 310 315 320 Lys Asp Lys Pro Leu Gly Ala Val Ala Leu Lys Ser Tyr Glu Glu Glu 325 330 335 Leu Val Lys Asp Pro Arg Ile Ala Ala Thr Met Glu Asn Ala Gln Lys 340 345 350 Gly Glu Ile Met Pro Asn Ile Pro Gln Met Ser Ala Phe Trp Tyr Ala 355 360 365 Val Arg Thr Ala Val Ile Asn Ala Ala Ser Gly Arg Gln Thr Val Asp 370 375 380 Glu Ala Leu Lys Asp Ala Gln Thr Asn Ser Ser Ser Asn Asn Asn Asn 385 390 395 400 Asn Asn Asn Asn Asn Asn Leu Gly Asp Asp Asp Asp Lys Cys Leu Pro 405 410 415 Ala Gly Gly Phe Cys Met Phe Arg Pro Met Asp Cys Cys Gly Asn Cys 420 425 430 Gly Cys Leu Tyr Pro Ala Gly Val Cys Tyr Gly Thr Arg Cys Glu Glu 435 440 445 <210> 131 <211> 25 <212> PRT <213> artificial sequence <220> <223> artificial sequence <400> 131 Cys Lys Ser Gly Gly Ala Trp Cys Gly Phe Asp Pro His Gly Cys Cys 1 5 10 15 Gly Asn Cys Gly Cys Leu Val Gly Phe 20 25 <210> 132 <211> 29 <212> PRT <213> artificial sequence <220> <223> artifical sequence <400> 132 Ser Gly Gly Ala Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn 1 5 10 15 Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly Cys 20 25 <210> 133 <211> 121 <212> PRT <213> Panax ginseng <400> 133 Met Glu Asn Lys Lys Val Ala Leu Val Val Val Ala Met Val Val Val 1 5 10 15 Leu Ile Ser Thr Phe Ala Pro Leu Ala Leu Ala Ala Asp Glu Ala Gly 20 25 30 Arg Ser Asp Gly Gly Asn Gly Asp Leu Ile Ala Val Glu Ser Val Ser 35 40 45 Arg Ser Asn Gly Gly Asn Gly Asp Ser Val Thr Val Asp Thr Val Ser 50 55 60 Trp Val Ser Ser Asn Arg Lys Thr Leu Arg Ser Ser Ile Phe Leu Pro 65 70 75 80 Gln Gly Tyr Leu Pro Asp Gly Gly Leu Gly Cys Lys Ser Gly Gly Ala 85 90 95 Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn Cys Gly Cys Leu 100 105 110 Val Gly Phe Cys Tyr Gly Thr Gly Cys 115 120 <210> 134 <211> 121 <212> PRT <213> Panax ginseng <400> 134 Met Glu Asn Lys Lys Val Ala Leu Val Val Val Ala Met Val Val Val 1 5 10 15 Leu Ile Ser Thr Phe Ala Pro Leu Ala Leu Ala Ala Asp Glu Ala Gly 20 25 30 Arg Ser Asp Gly Gly Asn Gly Asp Leu Ile Ala Val Glu Ser Val Ser 35 40 45 Arg Ser Asn Gly Gly Asn Gly Asp Ser Val Thr Val Asp Thr Val Ser 50 55 60 Trp Val Ser Ser Asn Arg Lys Thr Leu Arg Ser Ser Ile Phe Leu Pro 65 70 75 80 Gln Gly Tyr Leu Pro Asp Gly Gly Leu Gly Cys Lys Ser Ser Gly Ala 85 90 95 Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn Cys Gly Cys Leu 100 105 110 Val Gly Phe Cys Tyr Gly Thr Gly Cys 115 120 <210> 135 <211> 115 <212> PRT <213> Panax ginseng <400> 135 Asn Lys Lys Val Ala Leu Val Val Val Ala Met Val Val Val Leu Ile 1 5 10 15 Ser Thr Val Ala Pro Leu Ala Met Ala Val Asp Asp Ala Gly Ser Ser 20 25 30 Asp Gly Leu Ile Ala Val Glu Ser Val Ser Arg Ser Asn Gly Gly Asn 35 40 45 Gly Asp Ser Val Ala Val Asp Thr Val Ser Trp Val Ser Ser Asn Arg 50 55 60 Lys Thr Leu Arg Ser Lys Ile Phe Leu Pro Gln Gly Tyr Leu Pro Asp 65 70 75 80 Gly Gly Leu Gly Cys Lys Ser Ala Gly Thr Trp Cys Gly Phe Asp Pro 85 90 95 His Gly Cys Cys Gly Ser Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly 100 105 110 Val Ser Cys 115 <210> 136 <211> 42 <212> PRT <213> Panax ginseng <400> 136 Glu Ile Leu Pro Asp Gly Gly Leu Gly Cys Leu Lys Asn Gly Glu Phe 1 5 10 15 Cys Trp Gly Asp Pro Ser Gly Cys Cys Gly Asn Cys Gly Cys Leu Ile 20 25 30 Ile Pro Gly Val Cys Tyr Gly Thr Gly Cys 35 40 <210> 137 <211> 121 <212> PRT <213> Panax ginseng <400> 137 Met Glu Asn Lys Lys Val Ala Leu Val Val Val Ala Met Val Val Val 1 5 10 15 Leu Ile Ser Thr Phe Ala Pro Leu Ala Leu Ala Ala Asp Glu Ala Gly 20 25 30 Ser Ser Asp Gly Gly Asn Gly Asp Leu Ile Ala Val Glu Ser Val Ser 35 40 45 Arg Ser Asn Gly Phe Asn Gly Asp Ser Val Ala Val Asp Thr Val Ser 50 55 60 Arg Val Ser Ser Asn Arg Lys Thr Leu Arg Ser Asn Ile Phe Leu Pro 65 70 75 80 Gln Gly Tyr Leu Pro Asp Gly Gly Leu Gly Cys Lys Ser Ser Gly Ala 85 90 95 Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn Cys Gly Cys Leu 100 105 110 Val Gly Phe Cys Tyr Gly Thr Asp Cys 115 120 <210> 138 <211> 108 <212> PRT <213> Panax ginseng <400> 138 Met Glu Asn Lys Lys Val Ala Leu Val Val Leu Leu Ala Ala Met Ala 1 5 10 15 Val Leu Thr Asp Leu Thr Leu Ala Thr Asp Asp Lys Ala Gly His Ser 20 25 30 Asp Gly Gly Ala Asp Arg Ser Asn Gly Gly Asn Glu Val Leu Ile Asp 35 40 45 Ala Pro Gly Arg Ala Ser Val Tyr Lys Asn Leu Pro Leu Ser Arg Phe 50 55 60 Phe Leu Arg Glu Lys Tyr Leu Pro Asp Gly Gly Leu Gly Cys Ile Pro 65 70 75 80 Gly Gly Gly Phe Cys Met Phe Glu Pro Leu Ser Cys Cys Val Asn Cys 85 90 95 Gly Cys Ile Leu Val Pro Gly Val Cys Tyr Cys Gly 100 105 <210> 139 <211> 121 <212> PRT <213> Panax ginseng <400> 139 Met Glu Asn Lys Lys Val Ala Leu Val Val Val Ala Met Val Val Val 1 5 10 15 Leu Ile Ser Thr Phe Ala Pro Leu Ala Leu Ala Ala Asp Glu Ala Gly 20 25 30 Arg Ser Asp Gly Gly Asn Gly Asp Leu Ile Ala Val Glu Ser Val Ser 35 40 45 Arg Ser Asn Gly Gly Asn Gly Asp Ser Val Thr Val Asp Thr Val Ser 50 55 60 Trp Val Ser Ser Asn Arg Lys Thr Leu Arg Ser Ser Ile Phe Leu Pro 65 70 75 80 Gln Gly Tyr Leu Pro Asp Gly Gly Leu Gly Cys Lys Ser Gly Gly Thr 85 90 95 Trp Cys Gly Phe Asp Pro His Gly Cys Cys Gly Asn Cys Gly Cys Leu 100 105 110 Val Gly Phe Cys Tyr Gly Thr Gly Cys 115 120 <210> 140 <211> 121 <212> PRT <213> Panax quinquefolius <400> 140 Met Asp Asn Lys Lys Val Ala Leu Val Val Val Ala Met Val Val Val 1 5 10 15 Leu Ile Ser Thr Phe Ala Pro Leu Ala Leu Ala Ala Asp Glu Ala Gly 20 25 30 Arg Ser Asp Gly Gly Asn Gly Asp Leu Ile Ala Val Glu Ser Val Ser 35 40 45 Arg Ser Asn Gly Gly Asn Gly Asp Ser Val Thr Val Asp Thr Val Ser 50 55 60 Trp Val Ser Ser Asn Arg Lys Thr Leu Arg Ser Ser Ile Phe Leu Pro 65 70 75 80 Gln Gly Tyr Leu Pro Asp Gly Gly Leu Gly Cys Ile Ser Ser Gly Gly 85 90 95 Trp Cys Gly Phe Asp Leu His Gly Cys Cys Gly Asn Cys Gly Cys Leu 100 105 110 Val Gly Phe Cys Tyr Gly Thr Gly Cys 115 120 <210> 141 <211> 113 <212> PRT <213> Panax quinquefolius <400> 141 Val Ala Val Ala Met Val Val Val Leu Ile Ser Thr Phe Ala Pro Leu 1 5 10 15 Ala Leu Ala Ala Asp Glu Ala Gly Arg Ser Asp Gly Gly Asn Gly Asp 20 25 30 Leu Ile Ala Val Glu Ser Val Ser Arg Ser Asn Gly Gly Asn Gly Asp 35 40 45 Ser Val Thr Val Asp Thr Val Ser Trp Val Ser Ser Asn Arg Lys Thr 50 55 60 Leu Arg Ser Ser Ile Phe Leu Pro Gln Gly Tyr Leu Pro Asp Gly Gly 65 70 75 80 Leu Gly Cys Lys Ser Gly Gly Ser Trp Cys Gly Phe Asp Pro His Gly 85 90 95 Cys Cys Gly Asn Cys Gly Cys Leu Val Gly Phe Cys Tyr Gly Thr Gly 100 105 110 Cys <210> 142 <211> 121 <212> PRT <213> Panax quinquefolius <400> 142 Met Asp Asn Lys Lys Val Ala Leu Val Val Val Ala Met Val Val Val 1 5 10 15 Leu Ile Ser Thr Phe Ala Pro Leu Ala Leu Ala Ala Asp Glu Ala Gly 20 25 30 Arg Ser Asp Gly Gly Asn Gly Asp Leu Ile Ala Val Glu Ser Val Ser 35 40 45 Arg Ser Asn Gly Gly Asn Gly Asp Ser Val Thr Val Asp Thr Val Ser 50 55 60 Trp Val Ser Ser Asn Arg Lys Thr Leu Arg Ser Ser Ile Phe Leu Pro 65 70 75 80 Gln Gly Tyr Leu Pro Asp Gly Gly Leu Gly Cys Ile Phe Ser Gly Gly 85 90 95 Trp Cys Gly Phe Asp Leu His Gly Cys Cys Gly Asn Cys Gly Cys Leu 100 105 110 Val Gly Phe Cys Tyr Gly Thr Gly Cys 115 120 <210> 143 <211> 41 <212> PRT <213> Panax quinquefolius <400> 143 Ala Leu Pro Asp Gly Gly Leu Gly Cys Leu Lys Asn Gly Gln Phe Cys 1 5 10 15 Trp Gly Asn Pro Ser Gly Cys Cys Gly Asn Cys Gly Cys Leu Ile Ile 20 25 30 Pro Gly Val Cys Tyr Gly Thr Gly Cys 35 40 <210> 144 <211> 94 <212> PRT <213> Panax quinquefolius <400> 144 Met Val Val Leu Thr Asp Leu Ile Leu Ala Ala Asp Asp Met Ala Asp 1 5 10 15 His Ser Asp Gly Gly Thr Asp Ile Ser Asp Gly Gly Asn Glu Val Leu 20 25 30 Ile Asp Ala Ser Ala Gly Val Ser Phe Tyr Lys Lys Leu Pro Met Ser 35 40 45 Arg Phe Phe Leu Arg Glu Arg Tyr Leu Pro Asp Gly Gly Leu Gly Cys 50 55 60 Ile Pro Gly Gly Gly Phe Cys Met Phe Glu Pro Leu Ser Cys Cys His 65 70 75 80 Asn Cys Gly Cys Leu Leu Val Pro Gly Val Cys Tyr Cys Gly 85 90 <210> 145 <211> 94 <212> PRT <213> Panax notoginseng <400> 145 Met Ala Val Leu Thr Asp Leu Thr Leu Ala Ala Asp Asp Lys Ala Gly 1 5 10 15 His Ser Asp Gly Gly Ala Asp Arg Ser Asp Gly Gly Asn Glu Val Leu 20 25 30 Ile Asp Ala Pro Gly Gly Ala Ser Val Tyr Lys Asn Leu Pro Leu Ser 35 40 45 Arg Phe Phe Leu Arg Glu Lys Tyr Leu Pro Asp Gly Gly Leu Gly Cys 50 55 60 Ile Pro Asn Gly Gly Phe Cys Met Phe Glu Pro Leu Ser Cys Cys Val 65 70 75 80 Asn Cys Gly Cys Ile Leu Val Pro Gly Val Cys Tyr Cys Gly 85 90 <210> 146 <211> 83 <212> PRT <213> Panax quinquefolius <400> 146 Met Glu Asn Lys Lys Val Ala Val Met Val Val Val Leu Ala Ile Met 1 5 10 15 Leu Ala Leu Ala Ile Ala Ser Arg Glu Ala Gly His Ser Gly Asp Asp 20 25 30 Pro Gly Thr Gly Val Arg Lys Met Leu Arg Pro Glu Ile Ile Asp Pro 35 40 45 Asp Gly Ser Cys Leu Lys Val Gly Lys Ile Cys Leu Gly Arg Gly Leu 50 55 60 Lys Glu Cys Cys Pro Ser Ala Thr Cys Gly Cys Leu Leu Gly Phe Cys 65 70 75 80 Ile Lys Cys <210> 147 <211> 6 <212> PRT <213> artificial sequence <220> <223> artificial sequence <220> <221> MISC_FEATURE <222> (1)..(1) <223> X is Ac-K <220> <221> MISC_FEATURE <222> (6)..(6) <223> X is W-NH2 <400> 147 Xaa Ser Gly Gly Ala Xaa 1 5 <210> 148 <211> 6 <212> PRT <213> artificial sequence <220> <223> artificial sequence <220> <221> MISC_FEATURE <222> (1)..(1) <223> X is Ac-A <220> <221> MISC_FEATURE <222> (6)..(6) <223> X is W-NH2 <400> 148 Xaa Ser Gly Gly Ala Xaa 1 5 <210> 149 <211> 6 <212> PRT <213> artificial sequence <220> <223> artificial sequence <220> <221> MISC_FEATURE <222> (1)..(1) <223> X is Ac-K <220> <221> MISC_FEATURE <222> (6)..(6) <223> X is W-NH2 <400> 149 Xaa Ala Gly Gly Ala Xaa 1 5 <210> 150 <211> 6 <212> PRT <213> artificial sequence <220> <223> artificial sequence <220> <221> MISC_FEATURE <222> (1)..(1) <223> X is Ac-K <220> <221> MISC_FEATURE <222> (6)..(6) <223> X is A-NH2 <400> 150 Xaa Ser Gly Gly Ala Xaa 1 5 <210> 151 <211> 71 <212> PRT <213> Angiopteris evecta <400> 151 Pro Leu Thr Ala Leu Ala Ala Arg Asn Glu Ile Ile Ala Leu Asp Gly 1 5 10 15 Glu Ala Lys Asn Asn Gln Leu Asn Tyr Leu Ala Met Val Leu Asp Val 20 25 30 Asn Arg Pro Arg Asn Cys Ile Pro Lys Gly Gly Trp Cys Leu Phe Asp 35 40 45 Ile Met Gly Cys Cys Lys Pro Cys Gly Cys Leu Ala Gly Phe Cys Trp 50 55 60 Val Val Gly Asp Asp Cys Asn 65 70 <210> 152 <211> 106 <212> PRT <213> Amaranthus retroflexus <400> 152 Met Ala Ile Met Ile Lys Gln Asn Ala Ile Ile ...

Claims

1. A method for solid phase peptide synthesis of a ginseng peptide or a pharmaceutically acceptable salt thereof, wherein the ginseng peptide has an amino acid sequence as shown in SEQ ID NO: 1; wherein the method comprises the following steps: (a) synthesizing the ginseng peptide by stepwise coupling of Fmoc-protected, optionally further appropriately side-chain protected amino acids, dipeptides and / or oligopeptides on a solid support in a linear C-terminal to N-terminal manner, wherein a glycine residue is added at the position corresponding to position 24 of SEQ ID NO: 1 mediated by Fmoc-(Dmb)Gly-OH, wherein the addition of glycine residues other than the glycine residue at the position corresponding to position 24 of SEQ ID NO: 1 is mediated by Fmoc-Gly-OH; (b) cleaving the ginseng peptide from the solid support and deprotecting the peptide; And subsequently, (c) the ginseng peptide is subjected to organic oxidative folding to form a native disulfide connection, wherein the organic oxidative folding is performed under non-aqueous conditions and in a folding buffer comprising DMSO, cysteamine and an organic base selected from pyridine, imidazole and morpholine.

2. The method of claim 1, wherein step (a) comprises the following steps: (i) deprotecting the first amino acid attached to the solid support by removing a protective chemical group from the first amino acid; (ii) activating the chemical group on the second amino acid to prepare the second amino acid coupled to the first amino acid; (iii) coupling the activated second amino acid with the deprotected first amino acid to form a peptide consisting of the first and second amino acids; and (iv) sequentially deprotecting and coupling multiple amino acids into the growing peptide chain until the ginseng peptide is synthesized.

3. The method of claim 1 or 2, wherein the method comprises promoting at least one of the deprotection, activation and coupling steps by applying microwave energy.

4. The method of claim 1, wherein the folding buffer further comprises an organic solvent.

5. The method of claim 4, wherein the organic solvent is isopropanol.

6. The method of claim 1, wherein the organic base is morpholine.

7. The method of claim 1, wherein the organic oxidative folding is performed at 4°C.

8. The method according to claim 1, wherein the method comprises purifying the folded ginseng peptide or a salt thereof by reverse phase high performance liquid chromatography.

9. The method of claim 1, wherein the folding buffer comprises 10% by volume DMSO, 100 mM cysteamine, and 5-90% by volume of an organic base.

10. The method of claim 1, wherein in step (c), the ginseng peptide is diluted to a concentration of 0.1 mM to 1 mM.

11. The method of claim 1, wherein the folding buffer comprises cystamine.